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ALT Alanine aminotransferase 
Anti-HBc Antibodies to Hepatitis B core antigen  
Anti-HBc IgG IgG antibody to hepatitis B core antigen 
Anti-HBc IgM IgM antibody to hepatitis B core antigen 
Anti-HBe Antibodies to Hepatitis B envelope antigen 
Anti-HBs Antibodies to Hepatitis B surface antigen 
Anti-HCV Antibodies to Hepatitis C  
BCP Basal Core Promoter 
 cccDNA Covalently Closed Circular DNA 
CHC Chronic hepatitis C 
CMIA Chemiluminescent Microparticle Immunoassay 
EIA Enzyme Immunoassay 
ETV Entecavir  
FDA Food and Drug Administration 
HBcAg Hepatitis B Core Antigen 
HBeAg Hepatitis B Envelope antigen 
HBIG Hepatitis B Immunoglobulin 
HBsAg Hepatitis B surface antigen 
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HBV Hepatitis B virus 
HBV DNA Hepatitis B virus DNA 
HCC Hepato-cellular carcinoma 
HCV Hepatitis C virus 
HIV Human Immunodeficiency Virus 
ICBS International Consortium for Blood Safety  
IFN-α Interferon-alpha  
IRES Internal Ribosome Entry Site 
LdT Telbivudine  
LVD Lamivudine 
 MHL Major Hydrophilic Loop 
MU Million Units 
NAT  Nucleic Acid Amplification Technology 
NCR Non-Coding Region 
ng Nanogram 
NRTIs Nucleoside Reserve Transcriptase Inhibitors 
NRVRD Non-Remunerated Voluntary Repeat Donors  
OBI Occult Hepatitis B infection 
Peg-INF Pegylated interferon  
PEI Paul-Ehrlich Institute  
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RLUs Relative Light Units  
RNA Ribonucleic Acid 
RT Reverse Transcriptase  
RT-PCR Real Time - Polymerase Chain Reaction 
STD Sexually Transmitted Disease 
SVS Sustained Viral Response 
TDF Tenofovir 
Total anti-HBc Total Hepatitis B Core Antibody 
TTID Transfusion-Transmitted Infectious Diseases 
WHO World Health Organization 
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Safe blood and blood products should be offered to recipients in need for blood transfusion; however, safe 
blood transfusion remains a problem in developing countries where resources are limited and blood 
transmitted diseases are endemic [1]. Among transfusion-transmitted infections, hepatitis B virus (HBV) 
infection is regarded as the most common. The risk of transfusion-related infection with hepatitis B and 
hepatitis C viruses (HCV) and HIV-1 is reported as 1: 63,000; 1:103,000; and 1: 493,000 transfused-units 
respectively in a study conducted in five blood centres in different parts of the United States where prevalence 
of HBV is low [2]. In the area where hepatitis B is endemic including Vietnam and Cambodia the risk of HBV 
transmitted transfusion is probably higher and the infection occurs in part due to improper testing [3,4]. Blood 
donor screening for HBV surface antigen (HBsAg) is in place also in low-income countries. However, HBV 
transmission may still occur during the initial sero-negative-window period of an acute infection, upon 
improper testing and also during late stages where virus is still present (HBV-DNA positive) though HBsAg is 
negative, so-called occult hepatitis B infection (OBI) [5,6]. OBI may originate from recovered infections with 
persistent low level viral replication, from escape mutants blocking export of antigen, or from reduced HBV 
replication after co-infection with HCV; HBsAg may or may not be present [7,8]. 
HBV and HCV share the common routes of transmission and can be transmitted by sexual intercourse, contact 
with body fluids from infected persons and from infected mothers to their babies. The most frequently risk 
factors of HCV transmission are blood transfusions from infected donors, injections of drugs, unsafe 
therapeutic injections and other practice related to health care [9]. Blood contact is also identified as the most 
important means of HBV transmission among three main identified modes of HBV transmission [10]. The risk of 
HBV transmitted transfusion is associated with blood donations collected in window period (WP), false 
negative test results or from donors with Occult Hepatitis B infection (OBI) [4] characterized as the presence of 
HBV DNA in blood or tissues in HBsAg negative patients with or without antibodies to hepatitis B core antigen 
(anti-HBc) or hepatitis B surface antigen (anti-HBs). Transmission of HBV infection from hepatitis B surface 
antigen (HBsAg) negative- anti-HBc positive donors to recipients has been reported [11]. However, WP 
donations are more likely to transmit HBV than donations collected from OBI donors [12].  
Testing strategies for HBV infection in blood donors varies globally depending on the prevalence of HBV 
infection in a given country. Screening tests for HBsAg are performed to avoid transmission of HBV infection by 
blood or blood products in most countries [13] including Southeast Asian countries. The anti-HBc testing is used 
as a surrogate test in some countries such as United State and Japan in order to prevent blood donations from 
HBsAg negative infectious donors [14]. Under this screening strategy, any blood donor positive either of the 
tests is excluded due to on-going HBV infection or potential OBI. This combined strategy helps to eliminate HBV 
transmission from donors in the widow period (WP) with the absence of detectable HBsAg and the presence of 
anti-HBc and/or HBV DNA [2,15]. However, anti-HBc screening is not practical in intermediate and endemic 
HBV prevalence countries where up to 90% of adults are exposed to either past or on-going HBV infection [16]. 
As a result, vast numbers of blood donors are excluded. For this reason, some Southeast Asian countries 
including Taiwan, Vietnam, and Cambodia perform the screening tests for HBsAg in blood donors in order to 
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avoid a large exclusion of blood donors, ensuring reasonable blood stocks, but bearing the residual risk of post-
transfusion HBV infection, particularly in those blood donors who are in WP or potential OBI.  
In addition, the infectivity of OBI is not clear though several studies report that exclusion of anti-HBc positive 
donors regardless of anti-HBs titre probably decreases the rate of HBV transmission by blood transfusion 
[17,18]. One should take into account that many studies of transmission risks may have methodological flaws 
that make it hard to interpret the findings [4]. Still there are clear indications that both the viral load and the 
immune status of the recipient must be taken into consideration when assuming that the risk for transmission 
of virus is higher in low-income countries where large populations have deranged immune capacity from 
chronic malnutrition and endemic diseases. It is thus urgent to get at scientific estimates of the infectivity of 
OBI in blood donations [19].  
Accurate detection not only of HBV and HCV carriers, but also of anti-HBc-positive donors is an urgent issue in 
order to set standards for safe blood transfusion where HBV infections are endemic. ELISA test is considered as 
standard test for testing HBV and HCV in developing countries. However, the tests are expensive, require 
complex instrumentation, and are not feasible in rural remote district hospitals in low-income countries. Rapid 
tests may be feasible tools for blood donor screening in poor communities. It is well established that rapid tests 
may yield false test outcomes due to the prozone effect due to imbalance between antibodies and antigens. In 
addition, the rapid test-accuracy claimed by the producers is normally based on seroconversion test panels 
which do not necessarily reflect the antibody spectrum in the population studied. It is thus possible that 
accuracy tests on pre-arranged test panels may yield falsely high performance indicators.  
There seems to be large local variations in HBV prevalence rates in South East Asia. Previous studies report 
prevalence rates of HBV infection in Cambodia of 8% and HCV of 6.5% [20], and in Vietnam in the range of 8% 
to 25% [21,22]. Also studies in Thailand report large prevalence variations among different groups of the 
population [23]. However, the Southeast Asian populations so far studied have been relatively small; 











HEPATITIS B VIRUS 
CLASSIFICATION AND CHARACTERISTICS  
Hepatitis B virus belongs to the Hepadnaviridae family of the viruses. The entire virus is spherical particle with a 
diameter of 42nm, consists of an outer protein envelope and an inner 28 nm icosahedral core known as 
nucleocapsid. The outer envelope is composed of several proteins known as hepatitis B surface protein (HBs) 
which encase the nucleocapsid. The inner protein shell contains hepatitis B core protein.  
GENOMIC STRUCTURE OF HBV  
Hepatitis B genome is a single molecule of partially double-stranded circular HBV DNA and viral DNA 
polymerase. Its genome is a relaxed circular DNA of approximately 3,200 nucleotides consisting of a full-length 
negative strand and a shorter positive strand. The 5’ end of the negative strand is covalently linked to the viral 
reserve transcriptase. The 5’ end of the positive strand is linked to oligoribonucleotides [24]. 
 
Figure 1: Genomic structure of hepatitis B virus  
Rehermann B, Nascimbeni M. Immunology of hepatitis B 
virus and hepatitis C virus infection. Nat Rev Immunol 
2005; 5: 215–29 with permission. 
Figure 1 shows the genomic structure of hepatitis B virus 
(HBV). The inner circles represent the full-length negative 
strand (with the terminal protein attached to its 5′ end) 
and the incomplete positive strand of the HBV genome. 
The thin black lines represent the 3.5, 2.4, 2.1 and 0.7 kB 
mRNA transcripts, which are all terminated near the 
poly(A) (polyadenylation) signal. The outermost coloured 
lines indicate the translated HBV proteins: that is, large, 
middle and small HBV surface proteins, polymerase 
protein, X protein, and core and pre-core proteins.  
When hepatitis B virus enters the body, it encompasses the immune system and infects the liver cell. Firstly, 
virus attaches to the liver cells membrane, before it enters the liver cell. After virions enter hepatocytes, by an 
as-yet-unknown receptor, nucleocapsids transport their cargo – the genomic HBV DNA – to the nucleus, where 
the relaxed circular DNA is converted to covalently closed circulation DNA (cccDNA). The cccDNA serves as the 
template for the transcription of four viral RNAs (Figure 1), which are exported to the cytoplasm and used as 
mRNA for translation of HBV proteins. The longest (pre-genomic) RNA also functions as the template for HBV 
replication, which takes places in nucleocapsids in the cytoplasm. Some of the HBV DNA and polymerase-
containing capsids are then transported back to the nucleus where they release the newly generated relaxed 
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circulator DNA to form additional cccDNA. The blood of HBV infected patients contains 20-nm spheres that 
consist of HBsAg and host-devired lipids [24]. 
Unlike retroviruses, hepadnaviruses bind polymerase proteins into a stem-loop formation, subsequently 
packaged by core proteins in the golgi and secreted via exocytosis into the blood stream, where it can contact 
other liver cells and continue replication [24]. In some cases, all HBV DNA can accumulate in DNA of liver cell. 
The virus transcription may stop or take place slowly; only hepatitis B antigen (HBsAg) is produced, not 
producing the entire virus. 
GENETIC HETEROGENEITY OF HBV 
 
Figure 2: Worldwide distribution pattern of HBV genotypes and subgenotypes [25]  
Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virology Journal 2008; 
5:156. 
Based on the divergence over the entire genome sequence of more than 8% among HBV strains, eight 
genotypes of HBV have been identified namely A, B, C, D, E, F, G, and H [26,27]. With extensive phylogenetic 
analysis of HBV genome, sub-genotypes of genotypes A, B, C, D, F based on more than 4% intra-genotypic 
divergence have been found. So far, 5 sub-genotypes for each genotype A,B, C, D have been identified while 4 
sub-genotypes of genotype F have been well documented [28]. Having evolved distinctly in specific geo-ethnic 
populations, HBV genotypes/subgenotypes have a distinct geographical distribution pattern (Figure 2), which 
shows the distribution of HBV genotypes and geno-subtypes globally. 
Basically, HBV strains were classified by the existence of two pair of mutually exclusive serotype determinants 
‘d’/ ‘y’ and ‘w’/ ‘r’ in the HBsAg along with the main antigenic determinant ‘a’, therefore, 4 serotypes of HBV 
strains have been identified as adw, adr, ayw, or ayr. There is also documented that 9 serotypes as ayw1, ayw2, 
ayw3, ayw4, ayr, adw2, adw4, adrq+ and adrq- [29]. Genotypes of HBV have specific geographic distribution. 
Genotype A is found predominantly in Northwest Europe, North America, Central and sub-Saharan Africa; 
genotype B and C in Southeast Asia, China and Japan; genotype D in the Mediterranean, the Middle East, and 
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India; Genotype E in Africa; genotype F in America, Polynesia, and Central and South Africa; genotype D in the 
United State and genotype H in Central America [27,30]. 
Toan et al. (2006) reported in their study that genotype C, D and A was detected in Vietnam at 25.1%; 20.3%; 
and 18.1% respectively. Genotype A was significantly more frequent in asymptomatic and non-hepatocellular 
carcinoma (HCC) carriers while genotype C is significantly more frequent in HCC and asymptomatic patients 
[30]. 
A study done by Norder et al. (2004) analysing the sequences of 234 complete genomes and 631 HBsAg genes 
to assess the worldwide diversity of HBV, reported that sub-genotypes B and C distributed in different 
geographic regions, with B1 dominating in Japan; B2 in China and Vietnam; B3 in Indonesia; B4 in Vietnam, all 
strains contains specifying subtype ayw1. Sub genotype C1 was predominant in Japan, Korea, China; C2 in 
China, Southeast Asia and Bangladesh; and C3 composing specifying adrq- [31]. 
Genetic heterogeneity of HBV has clinical significance as some studies have shown that HBV genotypes and/or 
sub-genotypes can influence mutation escape, HBeAg seroconversion rates that could eventually influence the 





down regulate HBeAg production and are associated with chronic HBV infection 
leading to HCC [35], occur more often among patients who are infected with genotypes A, C and F [28]. 
Genotype C was observed more in patients with cirrhosis [36,37]. HBV genotype B is associated with a higher 
rate of IFN-induced HBeAg clearance compared to genotype C [38]. Escape mutants is also a matter of concern 
when considering the efficacy of HBV vaccine in a given population. Regarding this, efficacy of HBV vaccine 
depends on HBV genotype prevalence in a given population [39].  
SEROLOGIC MARKERS OF HEPATITIS B AND ITS SIGNIFICANCE TO DIAGNOSTIC CRITERIA 
 Figure 3: The serologic and clinical patterns observed during acute infection [4].  
Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 
48:1001–26 with permission. 
15 
 
Serological testing to diagnose HBV infection involves the measurement of a variety of distinct HBV specific 
antigens and antibodies that the host reacts to these antigens after initial HBV infection. Figure 3 shows the 
different serologic markers that appear in acute HBV infection. 
HEPATITIS B DNA (HBV DNA) 
HBV DNA can be detected very early after HBV infection (Figure 3) and generally indicates active viral 
replication. The presence of HBV DNA is a direct evidence of HBV in bloodstream. Quantitative test of HBV DNA 
can be used as an indicator of disease progression.  
HEPATITIS B SURFACE ANTIGEN (HBSAG) 
HBsAg is the first viral antigen to be detected appearing in plasma of patients with acute HBV infection before 
symptoms appear. The incubation of the Hepatitis B Virus (Hepatitis B) (time from the acquisition of HBV to the 
onset of clinical symptoms) is typically between 8 to 12 weeks (Figure 3). The first serologic marker to appear is 
hepatitis B surface antigen (HBsAg), which can initially be detected in serum from 1 to 12 weeks (average, 30 to 
60 days) after infection. The HBsAg level increases when symptoms appear and decreases after 2-3 months 
(Figure 3). The presence of HBsAg in plasma proves the presence of HBV DNA virus in hepatocyte. Testing 
HBsAg is an indicator of HBV infection. The presence of HBsAg for more than six months generally indicates 
chronic HBV infection. HBsAg is not detectable in patients with resolved HBV infection. 
A negative test for HBsAg in some acute HBV infectious patients might suggest that the current assay does not 
detect a very low level of HBsAg or HBsAg is neutralised by anti-HBs antibodies. 
HEPATITIS B E ANTIGEN (HBEAG) 
HBeAg develops one week after HBsAg is detectable. HBeAg usually disappears about 3 weeks before HBsAg 
disappears. The presence of HBeAg in serum of patients indicates a chronic HBV infection. The presence of 
HBeAg generally correlates with a higher degree of infectivity. Therefore, HBeAg-positive patients are potential 
HBV carriers to transmit the disease to others because the presence of HBeAg means that HBV is replicating. 
The risk of perinatal transmission of HBV is about 85-90% if the mother is both HBsAg-positive and HBeAg -
positive. 
HEPATITIS B CORE ANTIGEN (HBCAG)  
The HBcAg is an intracellular antigen synthesized within infected hepatocytes. HBcAg is not detectable in 
plasma. Anti-HBc antibodies can be detected in the sample of hepatocytes taken after a liver biopsy due to 
immunization upon sampling.  
TOTAL HEPATITIS B CORE ANTIBODY (TOTAL ANTI-HBC) 
The first detectable antibodies to appear around 8 weeks after infection with HBV are antibodies to HBV core 
protein (Figure 3). Anti-HBc appears 5 to 14 days after HBeAg appears and can be detected shortly before 
HBsAg in acute infection.  
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The initial antibodies are classified as IgM and IgG and generally appear after the appearance of HBsAg, but 
often before alanine aminotransferase (ALT) elevations. Anti-HBc IgM is present in the first weeks of the 
disease indicating current HBV infection. Anti-HBc IgG appears later and persists longer. Anti-HBc may persist 
months to years in convalescent period after acute HBV infections and persist longer in chronic HBV infections 
(Figure 3). Antibodies to HBcAg do not neutralise the virus and anti-HBc is not protective against HBV re-
infection [17,40]. 
HEPATITIS B E ANTIBODY (ANTI-HBE) 
Anti-HBe is usually detectable between 12 and 16 weeks, when HBeAg disappears (Figure 3). Anti-HBe is not 
detectable until the immune system has cleared most of the HBe antigens from the blood. The presence of 
anti-HBe generally indicates a good immune response to HBV infection.  
ANTI-HBS (ANTI-HBS) 
Anti-HBs antibodies appear after three-month of infection with HBV and normally at that time HBsAg 
disappears. Anti-HBs neutralize the HBsAg and is protective for re-infection. IgM anti-HBs is present in the 
acute period, IgG anti-HBs appears later and persist longer. The presence of anti-HBs is an indicator of 
recovery. Anti-HBs play an important role to protect patients from HBV re-infection, therefore, anti-HBs is a 
component to be used to produce HBV hyper-immune plasma. When vaccinated with HBV vaccine, anti-HBs is 
the only antibody present in bloodstream.  
IMMUNE RESPONSE TO HBV INFECTIONS 
SEROLOGIC RESPONSE TO ACUTE HBV INFECTION 
Figure 4 shows the immune response in acute HBV infections, followed by clinical recovery. After recovery, 
neutralizing anti-HBs and HBV-specific T cell persists for life [24].  
Figure 4:  immune response in acute HBV infections. 
Rehermann B, Nascimbeni M. Immunology of hepatitis B 
virus and hepatitis C virus infection. Nat Rev Immunol 
2005; 5: 215–29 with permission.  
The incubation phase defined as time from HBV infection 
to the onset of clinical symptoms is about 8 -12 weeks 
[41]. During acute infection, HBsAg is the first serologic 
marker to appear and can be detectable from 1 to 12 
weeks after initial infection. Soon after, HBeAg can be 
detected [42,43]. With onset of clinical symptoms, alanine 
aminotransferase level increases that reflect hepatic injury 
[44]. About this time anti-HBc IgM appears and then 
decline to undetectable levels within 6 months while anti-
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HBc IgG can last much longer.  
In a typical case of acute HBV infection, HBV DNA can be detectable in the circulation using PCR technique 




 genome up to six weeks 
before HBV DNA, HBeAg, HBsAg increases to their peaks. Approximately 10-15 weeks after infection, serum 
alanine aminotransferase (ALT) concentration starts to rise (Figure 4) [24].  
SEROLOGICAL RESPONSE WITH RESOLVED HBV INFECTION 
Following acute infection, the progress of serologic markers depends on the outcomes of the host immune 
response. Approximately 90% of adults will resolve while up to 90% infections in childhood develop chronic 
infection [24]. In resolved patients, HBsAg disappears in about 3-6 months, following the presence of anti-HBs 
that indicates recovery and protective immunity against re-infection. In the meantime, the disappearance of 
HBeAg occurs and development of anti-HBe becomes evident. In resolved HBV patients, anti-HBc persists for 
life.  
SEROLOGIC RESPONSE IN CHRONIC HBV INFECTION 
Chronic HBV patients have the similar serologic response in the acute phase as the resolved HBV patients. 
Persistence of HBsAg for more than 6 months indicates chronic HBV infection. In chronic HBV infection, HBsAg 
and anti-HBc IgG generally persist for life and HBV DNA can be detected by nucleic acid amplification. The 
presence of HBsAg and the absence of IgM anti-HBc also indicate chronic HBV infection. The presence of HBeAg 
indicates high HBV DNA and greater infectivity. 
Figure 5: Chronically evolving hepatitis B 
results from vertical transmission. 
Rehermann B, Nascimbeni M. Immunology 
of hepatitis B virus and hepatitis C virus 
infection. Nat Rev Immunol 2005; 5: 215–29 
with permission. 
Chronic hepatitis B infection is most 
commonly observed through vertical 
transmission from HBV infected mothers to 
neonate. The course of the disease includes 
several phases with different lengths. The 
immune-tolerant phase, which can last for 
decades, is characterized with high circulating HBV DNA and HBV e antigen (HBeAg) and normal alanine 
aminotransferase levels (Figure 5). Then it can transit to an immune-active phase with lower HBV DNA level 
detected, but liver diseases may be severe and progress to liver cirrhosis. The immuno-active phase can transit 
to a low replicative phase with the clearance of free HBeAg from the serum and appearance of HBeAg-specific 
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antibodies. In this phase, HBV DNA might not be detectable; alanine aminotransferase is at normal level and 
necro-inflammatory liver diseases improve [24]. 
EPIDEMIOLOGY AND TRANSMISSION OF HBV  
EPIDEMIOLOGY 
Hepatitis B is a serious public health problem globally and a major cause of chronic hepatitis, cirrhosis and 
hepatocellular carcinoma (HCC). There is estimated that about two billion people worldwide have infected with 
HBV and more than 350 million are chronic HBV carries, of whom 75% live in Asia and Western Pacific [45,46]. 
It is estimated that 15%-40% of chronic HBV patients develop cirrhosis, liver failure or HCC [47]. 
Prevalence of chronic HBV infection is classified as high where prevalence is more than 8% such as Southeast 
Asia, China, sub-Saharan Africa and the Amazon Basin; as intermediate where prevalence is 2%-7% including 
Eastern and Southern Europe, Middle East, Japan, and part of South America; and as low where prevalence is 
less than 2% in North America, Northern and Western Europe and Australia. In high endemic areas, 70%-90% of 
the population has a past or on-going serologic evidence of HBV infection and most infections were observed in 
infancy or childhood. In intermediate areas, 10%-60% of the population shows evidence of HBV infection and 
2%-7% are chronic carriers. Many infections occur in adolescent and adults, but infection during infancy and 
children still contribute at high rate. In low HBV prevalence areas, 5%-7.5% of population has evidence of 
serologic HBV infection, of which 0.5%-2% are chronic carriers. Most HBV infections occur in adolescent and 
young adults in high risk groups such as injection drug use, homosexual males, healthcare workers, patients 
given blood transfusion [48]. 
A study on prevalence of HBV infection in potential blood donors in rural Cambodia reported that the overall 
prevalence of HBsAg positive in the study population was 7.7% (95% CI: 6.2%-9.3%) and the prevalence of anti-
HBc sample was 58.6% [1]. The prevalence of HBV infection in blood donors in Thailand declined from 7.14% in 
1978 to 2.63% in 2009 resulting from an effective expanded immunization program against HBV [49]. In 13,897 
first time blood donors in Lao during 2003 to 2005 the prevalence of HBsAg was reported to be 8.7%; with a 
higher level in males (9.7%) than in females (6.2%) [50]. 
A retrospective study conducted in Malaysia on 44,658 voluntary blood donors between 2000 to 2004, 
revealed that the mean prevalence of hepatitis B infection among first time and regular blood donors were 
significantly different,1.8% and 0.4% respectively. Prevalence of HBV infection in male blood donors was at 
1.2% compared to 0.4% in female donors [51].  
TRANSMISSION OF HBV INFECTION 
HBV can be transmitted through contacts with body fluids from infected HBV patients. Blood is the most 
important route of HBV transmission, but other body fluids such as semen and saliva have been reported to be 
the source of transmission. So far, three main modes of HBV transmission have been identified: perinatal mode 
from infective mothers to their babies, sexual intercourse and parenteral/percutaneous routes. 
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Transmission of HBV from HBV infected mothers to their babies is the most important factors in high endemic 
HBV prevalence such as China and Southeast Asia. The transmission can occur during the perinatal period 
through three main routes: Trans-placental transmission of HBV in utero transmission during delivery; and 
postnatal transmission during care or breast milk [48]. For a child less than one year old who is perinatally 
infected with HBV, the risk of chronic HBV development is 90% due to the immature immune system [24]. 
In high endemic HBV areas, HBV is predominantly transmitted among young children through HBV infected 
mothers to their babies [52]. Infants born to chronic HBV infected mothers, especially positive HBeAg mothers 
are at high risk of becoming infected with HBV at birth. In East and Southeast Asia 35 to 50% of the women 
who are HBsAg positive are also HBeAg positive [53]. It is estimated that 65% to 90% of their infants will 
become infected, develops chronic HBV carriers; perinatal transmission results in 30-50% of all chronic HBV 
infections in high endemic countries [54].  
Transmission of HBV infection though sexual contacts has been reported as a major source of transmission 
globally, particularly in low endemic HBV prevalence countries. The highest risk of HBV as a sexually 
transmitted disease (STD) is considered to be where men have sex with men, resulting in 70% HBV infections in 
homosexual men. Sexual contacts of injection drug users and of sexual workers are at high risk of HBV 
acquisitions [16,55]. 
Injections of drugs, blood transfusions, acupuncture, casual accident in healthcare setting, tattooing and 
household contacts are also vehicles of HBV transmission. Although screening for HBV infection in blood 
donors has contributed considerably to the reduction of transfusion transmitted HBV infection, HBV infection 
after blood transfusion is still a matter of concern. Insufficient testing is probably the main cause of HBV TTID 
and blood donors with the presence of HBV DNA and absence of HBsAg, the so-called “Occult Hepatitis B 
Infection - OBI” can be infective [11]. This will be described in depth in the section “Occult hepatitis B and blood 
transfusion” in this thesis. 
PREVENTION AND TREATMENT 
PREVENTION 
There are several approaches in prevention of HBV infection including: safe blood products, behaviour change 
to prevent disease spread; passive immune-prophylaxis in those who have been exposed to HBV and active 
immunization. 
Deferral of blood donors with risk behaviour and improved screening have contributed to the reduction of HBV 
infection transmitted by blood transfusions. Use of condoms during sexual intercourse is commonly 
recommended not only for HIV prevention but also for HBV prevention. Increasing sensitivity of HBV assays 
also plays an important role in the management of HBV spread. Behaviour changes also involve activities such 
as health education for the public as well as targeting high risk groups.  
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Administration of Hepatitis B Immune Globulin (HBIG) is a passive immune-prophylaxis for prevention of HBV 
infection in those who may have been exposed. HBIG is made from human plasma from selected donors who 
already have a high level of antibodies to HBV. HBIG is recommended in four situations: new-borns of HBV 
infected mothers; after needle stick exposure; after sexual exposure; and after liver transplantation [48]. HBIG 
is recommended for all infants born from HBsAg positive mother immediately after delivery or within 12 hours 
after birth in combination of recombinant vaccine against HBV. It is reported that up to 90% has protective 
levels of antibodies protecting against perinatal acquisition of HBV [56]. HBIG mono-therapy at a high dose can 
prevent recurrence of HBV in from 60% to 80% of patients who have undergone liver transplantation [57]. 
Universal HBV vaccination programs 
Active immunization (HBV vaccination) is an important approach to decrease the risk of chronic HBV infection 
and the complications. The World Health Organization (WHO) recommended that vaccination against HBV 
should be included in national vaccine programs in all countries with HBV prevalence of 8% by 1991, more than 
8% by 1995 and all countries by 1997. The HBV vaccination program had been introduced in 154 countries by 
May 2002 [58] and 168 countries by the end of 2006 [59]. The effectiveness of universal infant HB vaccination 
is significant and reduction or eradication of chronic HBV infection has been recognized in many countries; 
however, there are challenges to achieve the goal of the universal immunization programs due to poor 
immunization delivery infrastructure, low coverage as well as sustainable financial situation [48].  
Hepatitis B vaccination is given for all infants at birth with three doses to ensure early protection. In neonates 
and infants, the result of vaccination is 98-100% protective anti-HBs levels equal or larger than 10 IU/L one 
month after completion of three doses of the HBV vaccine. Most children vaccinated at birth retain 
immunologic memory to hepatitis B vaccine for 15 years [59]. 
The impact of vaccination programs in Taiwan is illustrated as one of the most successful and effective public 
health programs to prevent chronic hepatitis B infection. Controlled randomized clinical trials on hepatitis B 
immunoglobulin and vaccine in Taiwan revealed an 80– 90% protective effect among infants of either HBsAg 
positive or HBeAg positive mothers. The prevalence surveys on infants born before and after the launch of the 
national vaccination program found a steady reduction in seroprevalence of hepatitis B surface antigen in 
Taiwan, with 78–87% effectiveness after the national vaccination program was implemented. Studies on the 
secular trend of liver disease risk also indicated a 68% reduction in mortality from fulminant hepatitis in infants 
and a 75% decline in the incidence of hepato-cellular carcinoma in children 6–9 years old after the national 
vaccination program began [60]. A review by Lee et al, revealed that the combination of vaccine plus HBIG is 
superior to vaccine alone in term of prevention of HBV infection [61]. The universal vaccination of newborn was 
introduced in Taiwan in 1983-1985. The impact of this program is that the HBsAg prevalence in children 
younger than 15 years decreased from 9.8% in 1984 to 0.7% in 1999, and further to 0.7% in 2004 [62]. In 
Malaysia, a cross-sectional study in school children aged 7-12 years from 1997 to 2003 showed a steady decline 
of the HBsAg prevalence from 2.5% for children born in 1985 to 0.4% among school children born in 1996 after 
the implementation of a universal new-born vaccination program in 1989 [63].  
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Universal infant HBV vaccination was implemented in Vietnam in 2003 [22] with the coverage of more than 
98% annually. Vaccination against HBV for new-borns within 24 hours after delivery has been preferably 
integrated in universal national immunization programs in healthcare settings particularly in hospitals. 
TREATMENT  
Treatment of chronic HBV patients is a broad issue beyond the scope of our current work; however, 
information provided in this section is an attempt to describe antiviral therapy approved worldwide and in Asia 
countries for chronic HBV management, briefly review some studied results regarding response and resistance 
of antiviral therapy.  
It is known that active replication is the key driver of liver injury and disease progress; therefore, viral 
suppression plays a very important role in chronic HBV management [64]. The primary goal of treatment of 
chronic HBV infection is to permanently suppress HBV replication. The suppression helps to reduce infectivity 
and pathogenicity of HBV. The decreased pathogenicity leads to the reduced hepatic necro-inflammation. 
Clinically, the short-term treatment goal is to obtain initial response in terms of HBeAg seroconversion and/or 
HBV DNA suppression, ATL normalization, and prevention of hepatic decompensation; to ensure sustained 
response to reduce hepatic necro-inflammation and fibrosis during/after antiviral therapy. The ultimate long-
term goal of treatment is to achieve durable response to prevent the progression to cirrhosis and /or HCC, and 
prolong survival [65]. 
Most antiviral drugs approved by Food and Drug Administration (FDA) for treatment of HBV infection are 
intended to target the reverse transcriptase (RT) and classified as nucleoside RT inhibitors (NRTIs) that suppress 
the viral replication. It is reported that HBV genotypes diversity affects NRTIs resistance. Also due to the S 
surface antigen and P genes overlapping in the large reading frame, genetic differences that affect the hepatitis 
B surface may change the viral polymerase sequence, function and drug susceptibility [66]. Currently six 
antiviral drugs have been approved the U.S. Food and Drug Administration for chronic HBV treatment including 
IFN-α, pegylated IFN-α, lamivudine, adefovir, dipivoxil, entecavir, and telbivudine. IFN-α (and pegylated 
formations) is the only drug that eliminates the covalently closed circular DNA (cccDNA) from hepatocytes and 
thus potentially curative [67]. IFN-α, lamivudine, adefovir, entecavir, telbivudine and PegIFN-α-2a have been 
currently licensed globally. Clevudine has been approved in Korea and Thymosin α1 has been approved in many 
countries in Asia [65].  
IFN-α treatment has been used for chronic HBV infection for more than twenty years. Several studies found 
that response to IFN-α treatment was observed to be higher in patients infected with genotype A (70%) 
compared to patients infected with genotype D and E (40%) [68]; and in patients infected with genotype B 
(41%) and with genotype C (15%) [36,69]. Interferon therapy had a higher rate of HBeAg seroconversion in 
patients infected with genotype A than in patients infected with genotype D or C [70,71]. A four to six month 
course of IFN-α treatment at a dose of 5 million units (MU) daily or 10MU three times a week obtained HBeAg 
loss in nearly 33% of HBeAg patients compared with 12% in control group. Small dose (5-6 MU three times 
weekly) has been used in Asian patients with similar efficacy. Retreatment in relapse patients with IFN-α 
treatment showed a response rate of 20-40% and when HBeAg seroconversion attained, it is sustained in more 
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than 80% of cases [72]. IPN-α treatment resulted in end-of-treatment biochemical and virological response in 
up to 90% HBeAg negative patients; however, sustained response rate was low: 10-15% with 4-6 month 
treatment; 22% with 12 month course; and 30% in 24 month treatment [65]. Main advantages of IFN-α include 
a course of finite duration with modest response, long-term benefits and no resistance, but having side effects 
such as influenza-like symptoms, fatigue, neutropenia, thrombocytopenia and depression [65,72]. 
A study in Asian patients showed that a 24-week treatment of weekly pegylated IFN-2α (40kD) achieved a 
higher HBeAg seroconversion than IFN-α-based therapy (33% vs. 25%; p>0.05). Several studies using Pegylated 
IFN-2β showed similar efficacy [72]. Pegylated IFN-2β was safe and effective in HBeAg positive chronic HBV 
patients with advanced fibrosis or cirrhosis as those with early state of fibrosis [73] Patients with chronic HBV 
infection who are lamivudine refractory and those who are lamivudine naïve response similarly to Pegylated 
IFN-2β [74]. 
Lamivudine (LVD) was the first safe, effective, and well-tolerated oral medication for the treatment of HBV 
infection. LVD resistance has been seen in approximately 20% of HBeAg seroconversion patients (a marker that 
is usually associated with a reduction in viral replication) after one year and up to 70% after five years [75,76]. 
The HBeAg seroconversion rate found similar in patients with HBV genotype B or C. 
Adefovir (ADV) has been approved by FDA only for the treatment of HBV infection. After a 5-year period 
treatment, it was estimated that 29% of ADV-treated patients were reported to develop ADV resistance as 
compared to 70% for LVD [77]. However, other studies documented that as many as 50% of ADV treated 
patients fail to obtain adequate viral suppression [78] and that high levels of ADV resistance occurrence were 
seen after 1-2 years of treatment [79,80]. Liu et al. indicated that patients with LVD-resistant mutations treated 
for 2–5 months with combination therapy of ADV and LVD obtained improved rates of viral suppression but did 
not improve biochemical indicators of liver health [81]. A study by Chan et al. (2007) demonstrated that 
virological suppression by ADV is not ideal in the majority of LVD-resistant patients. However, early treatment 
by ADV when HBV DNA is low played an importance to retain virological suppression [82]. 
Tenofovir (TDF) is used for the treatment of HIV infections and is known also to inhibit HBV polymerase. Jain et 
al. showed that combined LVD/TDF therapy suppresses synthesis of HBV DNA more effectively than mono-
therapy of either LVD or TDF alone [83]. More patients infected with HBV genotype A responded to TDF-based 
treatment better than the patients infected with non-A genotype HBV, regardless of therapeutic regimen or 
compliance, or prior antiretroviral treatment for those with HIV co-infection [83]. In vitro drug combination 
studies have revealed that TDF has an additive effect when combined with LVD, ETV, or LdT [84]. However, in 
Jain et al. the patients were HBV/HIV co-infected and so far LVD/TDF combination is not recommended as first-
line therapy in HBV mono-infected patients [83]. 
Entecavir (ETV) has several distinct advantages over LVD and ADV. ETV is known as the most potent inhibitor of 
HBVRT. It not only inhibits both wild-type and LVD-resistant HBV but also not associated with any major 
adverse effects. In addition, ETV has limited potential for development of resistance [85].  
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Telbivudine (LdT) is an orally administered nucleoside analogue, approved for the treatment of chronic 
hepatitis B, with good tolerance, lack of mitochondrial toxicity, and no dose-limiting side effects. In clinical trial, 
LdT gave more potent HBV suppression than LVD and ADV [65]. 
Although anti-viral therapy for HBV chronic management is approved; many of the drugs is not affordable to 
the average HBV patient, especially for those who live in developing Asian countries where hepatitis B infection 
is endemic and resources are limited [86]. The cost of the treatment has been a matter of concern not only for 
the patients but also for public health policies for decades. The universal infant vaccination program against 
hepatitis B virus proved one of the most successful and effective public health programs to prevent chronic 
hepatitis B infection globally; therefore, it should be encouraged with high coverage in all countries.  
SCREENING TESTS FOR HBV IN BLOOD DONORS (HBSAG, ANTI-HBC, HBV DNA) 
The screening programs for HBV infection in blood donors vary worldwide depending on the prevalence of HBV 
infection and financial situation in a specific country. Screening tests for hepatitis B antigen (HBsAg) are 
performed to prevent transmission of HBV infection by blood or blood products in addition to monitor the 
status of the patients in combination with other serological HBV markers in most countries [13]. HBsAg appears 
in infected patients from weeks to months after onset of infection and before symptoms starts. Some infected 
patients never have HBsAg positivity, but generally produce anti-HBc to respond to hepatitis B core antigen. 
The fact that there are some false negative for HBsAg is the reason for the performance of anti-HBc testing in 
some countries. However, determination of HBsAg negative/anti-HBc positive individual has been problematic 
for blood donor collection facilities [14]. In low HBV infection prevalence countries such as United States and 
Japan, screening for both HBsAg and anti-HBc is integrated into screening program for blood donors [87,88]. 
Under this regimen, any blood donor positive for either of the tests, were excluded because of current HBV 
infection or potential OBI. However, this combined strategy is not practical in intermediate and endemic HBV 
prevalence where up to 90% of adults’ population exposed to either past or on-going HBV infection [16] leading 
to a vast exclusions of blood donors. For this reason, some Asian countries including Taiwan, Vietnam, and 
Cambodia perform the screening tests for on-going HBV infection (HBsAg) in blood donors, not for past HBV 
infection (anti-HBc). This HBsAg screening program avoids a large exclusion of blood donation, maintaining 
reasonable blood stocks, but bearing the residual risk of post transfused HBV infection, particularly in those 
donors who are in WP or potential OBI. 
As HBV testing was improved and more sensitive after introduction of nucleic acid amplification technology 
(NAT), HBV DNA has been identified in HBsAg negative, anti-HBc positive blood donors. In low HBV prevalence 
areas, HBV DNA was found in less than 5% of HBsAg negative and anti-HBc positive blood units [89] whereas 
serum HBV DNA was found in 4-25% of HBsAg negative and anti-HBc positive individuals in high HBV 
prevalence [90–93]. It is reported that in high endemic countries, most HBV infections are transmitted through 
perinatal routes or early in childhood, therefore, a higher fraction of infected adults have late chronic HBV with 
the absence of HBsAg resulting in a higher rate of OBI in anti-HBc positive individuals in these regions [5].  
As mentioned above, OBI may derive from healthy chronic carriers without any serologic markers of HBV 
infection other than HBV DNA. Over time, antibody markers may become undetectable leaving HBV DNA the 
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only marker of the infection. In all cases, the viral load in OBI is usually low, often below 100 IU/ml. At these 
levels, HBV DNA measurement using NAT in pools is likely to be largely ineffective [7]. The efficacy of anti-HBc 
approach has been evaluated in low prevalence areas where a few seropositive samples contained HBV DNA. 
Data from 10 studies in seven Asian countries revealed that the prevalence of anti-HBc is from 7% to 43%, and 
about 5% (range: 0 -18%) of anti-HBc samples contained HBV DNA [17,94,95]. It can be concluded that the 
efficacy of anti-HBc screening program was relatively high in these regions where NAT is infeasible due to 
limited resources. 
In addition, current knowledge shows that anti-HBc testing has the potential of disqualifying majority of OBIs, 
leaving only the probably rare cases with HBV DNA alone undetected. Currently available HBV DNA assays with 
sensitivity of 20-50 UI/ml could only detect OBI with > 320-800 IU/ml when sample was diluted by 16 as it is 
when testing mini-pools of samples. However, many cases of OBIs in blood donors are below that viral load, 
therefore, enhancement of NAT sensitivity in Asia becomes a critical issue [5]. NAT HBV DNA assays have not 
eliminated the necessity for serological assays for HBV infected donors. It is hoped that NAT testing would 
reduce WP donors; identify low viral levels of HBV; provide another mechanism for re-entry of HBsAg false 
negative donors; and replace serological testing [14].  
Raimondo et al. (2010) stated that HBsAg negative, HBV DNA positive blood have to be considered infectious 
and may account for HBV transfusion-transmitted infection. More importantly, HBV-DNA (NAT) is considered to 
be the only reliable diagnostic marker of OBI [96]. Blood donor screening for anti-HBc and NAT testing have 
been implemented in some developed countries in order to avoid OBI. However, anti-HBc testing is not 
practical in countries with endemic HBV prevalence. More importantly, the NAT technology is also not feasible 
in low-income countries, especially in low financial resource settings due to its high cost. 
OCCULT HEPATITIS B AND BLOOD TRANSFUSION  
Recently there has been much concern about “Occult Hepatitis B infection (OBI)” in blood transfusion settings. 
OBI is characterized as the presence of HBV DNA in blood or tissues in HBsAg negative patients with or without 
antibodies to hepatitis B core antigen (anti-HBc) or hepatitis B surface antigen (anti-HBs) [11]. Allain 2004 
indicated several clinical conditions where OBI is found: a) at the time of recovery from past infection 
characterized with detectable anti-HBs; b) in individuals with chronic hepatitis B with surface antigen escape 
mutants that are not detected by current assays; c) in individuals with chronic hepatitis B carriers without any 
serologic markers other than HBV DNA; d) in individuals with chronic hepatitis at the healthy carriage state 
indicated by the presence of anti-HBe [97].  
In 2008 International workshop on OBI, experts from the European Association for the Study of the Liver 
defined OBI as the ‘presence of HBV DNA in the liver (with detectable or undetectable HBV DNA in the plasma) 
of individuals testing HBsAg negative by currently assays’. The experts in the meeting also introduce an OBI cut-
off for HBV DNA of less than 200 IU/ml [98]. OBI individuals are also classified as either sero-negative with the 




EPIDEMIOLOGY OF OBI  
The prevalence of OBI varies greatly between geographic areas as well as among patients tested with different 
assays for routine serologic or NAT screening [4,97]. The prevalence of OBI is correlated with the prevalence of 
HBV infection in a given population [100,101]. Patients from highly endemic HBV prevalence areas are more 
likely to develop OBI [102] as most patients in these areas are infected during perinatal or during childhood 
responsible for high proportion of OBI in anti-HBc positive populations [5]. 
Prevalence of OBI was observed in 0.1 to 2.4% in HBsAg negative anti-HBc positive blood donors in Western 
countries where only 5% of the population has evidence of exposure to HBV infection. Meanwhile, up to 6% of 
OBIs were identified in endemic areas where 70% -90% of population have prior exposure to HBV [4]. In 
Western countries, OBIs are observed in range of 1:2,000 to 1: 20,000 donation collected and are more 
frequently found in male over 50 years old with normal ALT and low viral DNA. Most OBI donors are anti-HBc 
positive or absence of anti-HBs [103–106]. 
The prevalence of OBI is reported 16% in general population with normal ALT level in Korea [107], 10.6% in 
HBsAg negative healthy people in China [108]. The rate of detected HBV DNA was observed highest in patients 
positive for anti-HBc alone; average in those positive with both anti-HBc and anti-HBs; and lowest in those 
whose sera are negative [101]. Allain (2004) reported that HBV DNA was observed 0% to 7.7% from either 
blood donors or in the general population in Northern Euro and North America with low HBV prevalence [97]. 
Study in Taiwan reported that HBV DNA is detected in 7.5% among 147 stored donated blood samples [3]. The 
review by Allain and Candotti (2012) on OBI prevalence from blood donors in different studies in China, 
reported a range between 1:600 and 1: 21,000 blood units with a mean about 1: 1,000 blood donors [109]. OBI 
prevalence in blood donors in Taiwan was reported approximately 1: 1,000 blood units [110,111]. 
There are several possible explanations for the mechanism of OBI. Mutations in regulatory regions of HBV 
genome that prevent HBsAg production and viral replication may be the first possible explanation. Any 
mutations in the pre-S/S region may cause the change of HBsAg antigenicity and inhibition of anti-HBs 
production [11]. Mutations in the pre-S1 region may terminate the induction of HBV large HBV protein, decline 
the formation of HBV virions, and avoid interaction of HBV in hepatocytes. Current studies demonstrated the 
evidence of numerous mutations and deletions in OBI genome, but the overall locations of mutations are 
similar in occult and non-occult blood samples. Differences in the methylation pattern between occult and non-
occult blood samples also were identified in a study done by Vivekanandan [112]. The study done by 
Weinberger (2000) indicated that the major hydrophilic loop (MHL) is the area of increasing genetic variability. 
The frequency of mutation in MHL of OBI patients (22.6/1000 amino acid) was significantly higher compared in 
non-MHL (9.4/1000 amino acid)[113]. 
Another possibility is the persistence of immune complexes consisting of HBsAg bound to anti-HBs. A study in 
11 Japanese patients showed that the level of free and Ig-bound HBV is equal in acute phase, Ig-bound HBV is 
dominated in WP in spite of the presence of free HBV, and free HBV is not detectable after sero-conversion. 
The authors predicted that immune complexes that occur after sero-conversion are not infectious and HBV 
reservoir likely takes place in the liver or peripheral blood monocular cells [114]. 
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Viral interference in co-infection with another virus is another explanation for the existence of OBI. Study of 
OBI in patients co-infected with HCV shows that HBV specific transcripts and HBV antigens declined two to 
fourfold by the presence of HCV gene structure and the secretion of HBV viral particles was suppressed by 20 
fold. The authors speculated that the core protein of HCV serves as a gene-regulatory protein in this case [115].  
Another possible explanation for the existence of OBI is the presence of a block to secretion of free HBsAg 
resulting in the only secretion of Dane particles without increased HBsAg in the serum. Change in the Pre S 
domain may be the reason to limit virion excretion [116].  
CLINICAL SIGNIFICANCE OF OBI IN BLOOD DONATION 
OBI after acute HBV infection 
Recovered patients from acute HBV infection might carry HBV genome for many years without any clinical or 
biochemical evidence of liver diseases [114,117]. Whether these patients with this disorder are at risk for 
transmitting HBV infection to others is a matter of concern. It is reported that in immune-competent patients 
who have developed anti-HBc and anti-HBs, no transmission of HBV has been observed in blood donations [4].  
OBI in Blood transfusion and Infectivity 
It is generally accepted that not all OBI donors transmit HBV infection to recipients. Anti-HBc is the first 
antibody to appear in HBV infection and remains persistence for life. This antibody test may be positive without 
the presence of both HBsAg and anti-HBs antibodies; during window period; before the appearance of anti-HBs 
antibodies; or in resolved HBV patients. It is documented that anti-HBc antibodies are not protective [17,40] 
whereas a certain amount of anti-HBs antibodies are protective by neutralizing the antigen and avoiding 
infectivity. Patients with anti-HBs antibodies may neutralize a certain amount of virus upon re-infection thereby 
not being infected upon transfusion of OBI blood donors.  
There are also other possible explanations why not all recipients of HBsAg negative HBV DNA positive blood 
donors develop HBV infection upon transfusion. These explanations include: “1) vaccination or prior disease 
induce immunity to HBV; 2) concurrent infusion of anti-HBs in another blood components; 3) presence of 
immune complexes; 4) inocula below the minimum infectious doses; 5) presence of defective or replication-
incompetent virions; and 6) viral interference from another pathogen” [118].  
Like other viral infections, HBV infectivity depends on three main factors: the infectious dose, the level of 
neutralizing antibodies and the immuno-competence of the host. It is documented that blood components 
from HBV OBI donors were not infectious in immuno-competent recipients, but infective in immuno-
suppressed recipients. It has been accepted that when HBV DNA is present, infectivity may occur, however, the 
viral load needed to infect has not been documented in human so far [5,14].  
Post-transfusion HBV from OBI blood donors is detected in 1: 60,000 transfused units in low prevalence areas 
[2,17], while in hepatitis B endemic areas transmission rates are probably much higher and occur in part due to 
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improper testing [3,4]. Residual transfusion transmitted HBV risk in repeat-donors is estimated to be 0.69-8.69; 
7.5-15.8; and 30.6-200 per million donations in low, moderate and high HBV prevalence, respectively [119]. 
The residual risk of transfusion-transmitted HBV is mainly associated with blood donations with the absence of 
detectable HBsAg that have been drawn either in a window period (WP) defined as time between infection and 
detection of viral antigen or antibody markers, or during later stages of infection [4,119]. WP donations are 
more likely to transmit HBV than donations collected from chronic OBI [12]. The risk of transmission is high in 
blood donors with absence or low level of anti-HBs. Blood components containing anti-HBs even at a certain 
level, do not appear to transmit HBV, only 10% of blood with low anti-HBs were infectious [7]. The risk of 
transmission is not significant with the presence of anti-HBs in the blood regardless of anti-HBc levels. 
However, caution should be taken when immune-deficient patients receive anti-HBc-positive, anti-HBs-positive 
donations [119].  
Studies in Europe and North America revealed that nearly 90% of blood donors who have recovered from an 
HBV infection are anti-HBc antibody and anti-HBs antibody positive. Donors with anti-HBs ≥ 100IU/L are 
presumable non-infectious, those with no anti-HBs or anti-HBs <100IU/L are potentially infectious [119]. Study 
in Japan showed that no HBV infection was observed in recipients of HBsAg negative-HBV DNA -positive OBI 
with anti-HBs antibodies present. The risk of post transfusion infection seems to be negligible when blood 
donors carried anti-HBs antibodies at a certain level of 100-200 IU/L. Some other studies confirm that there is a 
high risk of HBV post transfusion when anti-HBs negative blood from OBI donors is transfused to susceptible 
recipients [12]. Anti-HBs in the recipient of OBI blood may also be protected from HBV infection. 
 OBI with HCV infection 
HCV and HBV infections share the similar transmission routes; therefore, co-infection of HBV and HCV occurs. 
There is more association between the prevalence of anti-HCV antibodies and the prevalence of anti-HBc 
antibodies compared to the presence of HBsAg. HCV infected patients appear to have higher prevalence of OBI. 
It is reported that HBV DNA is detected in one-third of HBsAg negative HCV carriers in Mediterranean basin and 










HEPATITIS C VIRUS 
In the middle of 1970s, there were epidemiological evidences that some patients, who had been given blood 
transfusion, developed liver disease several years after transfusion. In order to distinguish this kind of disease 
with known HBV and HAV, called “non-A, non-B Hepatitis, this pathogen was identified in 1989 and named 
Hepatitis C virus [122]. 
CLASSIFICATION AND CHARACTERISTICS  
Hepatitis C virus is a single strand RNA virus. It is a member of family Flaviviridae, responsible for acute and 
chronic hepatitis C infection in about 3% of human population [123]. Based on the analysis of nucleic acids of 
its genome, six major genotypes 1-6 and a large diversity of subtypes have been identified and distributed in 
different regions in the world [124].  
Clinically, patients with acute hepatitis C infection often are asymptomatic in exception for some cases that 
demonstrate jaundice. About 80% - 85% of acute HCV infections develop into chronic infections. The liver 
failure in chronic cases is not only caused by the virus, but also from autoimmune pathology. It has been 
estimated that HCV accounts for 27% of cirrhosis and 25% of hepatocellular carcinoma globally [125] 
GENOME STRUCTURE  
HCV is classified in the Hepacivirus genus belonging to the Flaviviridae family. HCV has a positive strand RNA 
genome containing 9,460 ribonucleotides. It’s genome is composed of a 5’ non-coding region (NCR), which 
includes an internal ribosome entry site (IRES), a large open reading frame that encodes at least 10 structural 
and non-structural proteins, and a 3’-NCR. The structural proteins of hepatitis C virus include the core protein 
and the envelope proteins, E1 and E2. The non-structural proteins include the p7 ion channel, the NS2-3 
protease, the NS3 serine protease and RNA helicase, the NS4A polypeptide, the NS4B and NS5A proteins and 
the NS5B RNA-dependent RNA polymerase (RdRp) [126].  
 
Figure 6: Genetic organization and poly-protein processing of hepatitis C virus (HCV)[126]  




The 9.6-kb positive-strand RNA genome is schematically depicted at the top (Figure 6). Simplified RNA 
secondary structures in the 5′- and 3′-non-coding regions (NCRs) and the core gene, as well as the NS5B stem-
loop 3 cis-acting replication element (5B-SL3) are shown. Internal ribosome entry site (IRES)-mediated 
translation yields a poly-protein precursor that is processed into the mature structural and non-structural 
proteins. Amino-acid numbers are shown above each protein (HCV H strain; genotype 1a; GenBank accession 
number AF009606). Solid diamonds denote cleavage sites of the HCV poly-protein precursor by the 
endoplasmic reticulum signal peptidase. The open diamond indicates further C-terminal processing of the core 
protein by signal peptide peptidase. Arrows indicate cleavages by the HCV NS2–3 and NS3–4A proteases. Dots 
in E1 and E2 indicate the glycosylation of the envelope proteins (4 and 11 N-linked glycans, respectively, in the 
HCV H strain) [126].  
GENETIC HETEROGENEITY OF HCV 
There are six major HCV genotypes (genotypes 1-6). It is reported that around 60% of HCV infections are 
caused by type 1a and 1b [127]. Genotypes 1, 2, and 3 of the Hepatitis C virus (HCV) are widely distributed 
throughout Western countries and the Far East (Japan, China, Taiwan, and Thailand). Types 5 and 6 are mainly 
confined to South Africa and Southeast Asia, respectively. In contrast, type 4 is predominant in the Middle East 
and Central Africa [128]. Genotype 6 viruses are predominant in Southeast Asia including Vietnam, Indonesia, 
Thailand, Cambodia, Myanmar [129]. Currently 17 subtypes (6a-6q) of genotypes 6 HCV have been identified 
based on complete genome analysis [130]. Subtype 6r and 6s existence was recently proposed according to 
sequence analysis of core/E1 and Ns5B from HCV strains of Cambodian immigrants in Canada [131]. HCV 
genotypes 7, 8, 9 have been identified only in Vietnamese patients [132] whereas HCV genotypes 10, 11 are 
found in Indonesian patients [133]. 
HCV subtypes 1a and 1b are most commonly distributed in The United State and predominant in Europe 
[128,134–136]. Subtype 1b is found in Japan accounting for up to 73% of HCV infections [137]. While HCV 
subtypes 2a, 2b are relative common in North America, Europe, and Japan; HCV subtype 2c is commonly 
identified in North Italia. HCV 3a is found mainly in intravenous drug users in Europe and the United State 
[138]. 
IMMUNE RESPONSE TO HCV INFECTION 
HCV concentration reaches high serum level within 1 week of infection [139,140]. Adaptive cellular immune 
responses are postponed by at least one month and humoral immune responses are delayed by at least 2 
months. After the first weeks of infection, the rate of acceleration of viral titre occurs slowly. Approximately 8-
12 weeks after HCV infection, HCV RNA concentration decreases when serum ALT level reaches its peak (Figure 
7). HCV specific antibodies might become detectable around this time. Most acute HCV infected patients 
develop chronic hepatitis C. Some acute HCV patients recover and have negative test for HCV RNA in current 
assays. HCV specific antibodies titre reduces and might be absent completely 10-20 years after recovery, 
therefore, complete clearance of HCV RNA might be obtained by at least a group of patients [141,142]. 
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Figure 7: Immune response of HCV infection [24].  
 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 
2005; 5: 215–29 with permission. 
The figure demonstrates the immune response in acute HCV infections. The development of HCV specific 
antibodies may vary and the clearance of the virus might occur either before development of a measurable 
humoral response or even in the absence of development of a detectable antibody response. Incubation phase 
and acute phase describe alanine aminotransferase (ALT) levels and have no implication of clinical symptoms. 
Most cases of HCV infections are asymptomatic. 
The figure illustrates also immune response in chronic HCV infections. HCV RNA titres decline by 2-3 logs after 
the ALT levels reach its peak, but then remain steady during the chronic HCV infection. 
EPIDEMIOLOGY AND TRANSMISSION OF HCV  
Up to 170 million people worldwide are currently infected with HCV infection, which is causing chronic liver 
diseases, inflammation, and long-term complications. HCV infection is a public health problem in developing 
countries including Asia and Africa [123]. The estimated prevalence of HCV infection in Southeast Asian 
countries are 2.0 to 3.8% for general population [23,143]; 12.5% for patients with chronic liver diseases [144] 
and more than 90% for injecting drug users [145]. HCV affects approximately 32 million people in Southeast 
Asia making the HCV disease burden is higher than a total of 22 million HCV infected persons from Europe, 
North America, and South America in combination [146,147].  
In Vietnam, the prevalence of HCV infection was reported at 2-2.9%, blood transfusion was identified as the 
predominant risk factor and the most common genotype are 1 and 6 [148]. A study in rural Thai Binh province, 
Vietnam, reported that HCV prevalence in general population was 1% (95% CI 0.4%-1.9%) with no significant 
association between genders. There is a significant association between HCV infection and hospital admission 
and tattoos practice [149]. In Thailand, prevalence of HCV in blood donors increased from 1.6% in 1991 to 
1.86% in 1994, thereafter it was reported to decline to 0.51% in 2009 [49]. A study on 13,897 first time blood 
donors in Lao PDR from 2003 to 2005 shows that the prevalence of anti-HCV positive blood donors was 1.1% 
[50]. A recent study on HCV infection in potential blood donors in rural area conducted in Samlot and Pailin 
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communities, Battambang province, Cambodia reported an overall prevalence of HCV infection was 14.7% 
(95% CI: 12.7%-16.7%) in the study population, 17% in Samlot and 12.3% in Pailin [1]. Higher prevalence of HCV 
infection in Cambodia compared to neighbouring countries is interesting, but difficult to explain.  
A systematic review of HCV epidemiology in Asia, Australia and Egypt from 690 relevant articles among 7,770 
articles done by Sievert W and co-authors estimated that 49.3 to 64.0 million adults in Asia, Australia and Egypt 
are anti-HCV positive. While a relatively high prevalence of HCV infection observed in Egypt (15%); Pakistan 
(4.7%) and Taiwan (4.4%), most other countries had prevalence from 1 to 2% of HCV infection. Blood 
transfusions and nosocomial infections are common risk factors in the region. Genotype 1 was common in 
China, Australia, Taiwan and other countries whereas genotype 6 was identified in Vietnam and other 
southeast countries [148].  
HCV is usually transmitted by infected blood, sexual intercourse, contact with body fluids of infected HCV 
persons and from infected HCV mother to their babies [9]. The most frequently risk factors for HCV 
transmission are blood transfusions from unscreened donors; injection drug use; unsafe therapeutic injections; 
and other improper practice related to health care [123]. In developed countries, drug use is the primary cause 
of transmission for HCV infection, such as in USA and Australia where prevalence of HCV infection in drug users 
is reported 68% and 80% respectively [150,151]. Contaminated injection equipment was identified as the major 
risk factor for HCV infection in several countries such as Egypt, India. Blood-borne transmission is the most 
common transmission route of HCV infection worldwide [123]. The risk of transfusion-related infection with 
hepatitis C, hepatitis B, HIV-1 was reported as 1:103,000; 1: 63,000; 1: 493,000 transfused-units respectively in 
a study conducted in five blood centres in different parts of the United States where prevalence of HBV is low 
[2].  
 Classification of HCV infection as acute or chronic depends on the duration of virus’ existence in the host body 
[9]. Acute HCV infection occurs during six months after exposed to HCV. The acute state of HCV infection is 
characterized with elevated serum alanine aminotransferase (ALT) level and jaundice which accounts for up to 
25% of HCV cases [127]. Approximately 80% of acute HCV infections are asymptomatic and difficult to diagnose 
[152]. The remaining 20% of acute cases are symptomatic with poor appetite, abdominal pain in right upper 
abdominal quadrant, joint and muscle pains, nausea, vomiting and fever [122,127,152]. 
Acute HCV infection becomes chronic HCV disease if HCV-infected person is not able to clear the virus within 6 
months of infection without any therapeutic intervention. Most chronic HCV infected persons show no 
symptoms until serious complications appear generally 20 years after initial infection. These complications 
include hepatocellular carcinoma, liver failure, and cirrhosis [9]. About 10% to 20% of individuals with chronic 
HCV infections regardless of country of origin or risk factors, develop cirrhosis, resulting in up to 5% 





HEPATITIS C DIAGNOSTIC ASSAYS 
Diagnostic tests for HCV infections include serologic assays for HCV antibodies and molecular test for viral 
particles. Screening tests for HCV antibody detection was introduced in 1989 and have resulted in the progress 
in early detection of HCV infection and contributed to the reduction of transfusion-related infections. The first 
serologic assay for HCV infection was an enzyme immunoassay for antibody detection. The currently used 2nd 
and 3rd generation enzyme immunoassays have a higher sensitivity containing core protein as well as non-
structural proteins 3 and 4 ( non-structural protein 5 in 3rd generation) and can detect antibodies within 4 to 
10 weeks after initial infection [153]. The recombinant immune-blot assay has been used to confirm antibody 
assays. It uses antigens similar to those for the enzyme immunoassay but in an immuno-blot format so that 
responses to the individual proteins can be identified. A positive assay is defined by the detection of antibodies 
against two or more antigens; and negative assay by the detection of antibodies against a single antigen [153]. 
The use of a recombinant immuno-blot assay to confirm results is normally recommended only in low risk 
setting for example for blood donors [154]. Recently, molecular assays for HCV RNA detection have been 
produced as qualitative and quantitative tests. PCR technique for qualitative HCV RNA assays has a lower limit 
of detection of 100 copies of HCV RNA per millilitre [155]. There tests are of choice for confirmation of viraemia 
and assessment of treatment of response. A qualitative PCR assay can also be used in HBV-inspected patients 
with negative results on enzyme immunoassay, in HBV-infected patients without identifiable course, and in 
patients with known reasons for false negative results on antibody assays [153].  
Recently there was a new enzyme immunoassay developed for the simultaneous detection of HCV core antigen 
and anti-HCV antibodies (Monolisa HCV Ag/Ab ULTRA; Bio-Rad). In terms of sensitivity, the performance of this 
test was not as high as that observed by HCV core Ag assays (73.8% and 96.9% of positive samples for HCV core 
Ag blood screening assay and trak-C assay respectively). However, this HCV combined assay reduces the 
window period to 21.6 days and 30.1 days compared with that of the most sensitive assays and Monilisa HCV 
Ab assay respectively, and provides a notable improvement for early detection of HCV infection during window 
period, especially in the early phase when antibodies are undetectable compared with previous anti-HCV 
assays. This combined assay also provides a new alternative to directly detection of viraemia with NAT or an 
HCV specific assay particularly with regard to cost, organization, emergency, and logistic difficulty. It could be 
performed for blood screening in low resource settings where NAT or HCV core antigen assays are not 
affordable and/or infeasible [156]. 
Routine HCV screening is performed in blood banks in Asia including Vietnam. The most widely used anti-HCV 
screening tests are enzyme immunoassays. Real Time Polymerase Chain Reaction (RT-PCR) is used for detection 
of HCV RNA. In acute HCV infections, anti-HCV is positive after two months of initial infections; 60% - 80% of 
HCV acute infections become positive after six months. The presence of HCV RNA in serum is the most reliable 
indicator of HCV infection, however, the presence of anti-HCV antibodies in serum or elevated ALT level at least 
10 fold of upper limit of normal range can also be indicator of HCV infection [122,127]. Chronic HCV infection is 
identified by the presence of anti-HCV and the elevation of ALT levels for more than 6 months [122]. 
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PREVENTION AND TREATMENT 
Currently, there is not an effective vaccine to prevent HVC infection. It has been difficult to develop a single 
effective vaccine against all types of the virus. The main reasons include the genetic diversity among HCV 
genotype and the mutation rate of HCV virus [9]. Therefore, immunotherapy is given as HCV treatment.  
The goal of HCV treatment is to avoid development of chronic infection, increase the quality of life for patients 
and prevent morbidity and mortality. Antiviral therapy based on the combination of pegylated interferon and 
ribavirin has obtained an acceptable response rate [157]. The type and duration of therapy administered for 
HCV patients depend on a number of factors such as genotype of the virus, age, gender, the state of fibrosis, 
body mass index, insulin resistance, co-infection with another hepatitis virus or with human immune-deficiency 
virus (HIV) [9,158]. The viral genotype is the most important factors affecting the type and duration of therapy 
and treatment outcomes; therefore, it is recommended that the genotype of a specific infection should be 
confirmed in order to plan an appropriate therapeutic regime. Eleven HCV genotypes have been identified so 
far, but only genotypes 1,2,3 are distributed globally and about 60% of HCV infection are caused by type 1a and 
1b [127]. It is reported that Interferon (IFN) treatment is more effective against HCV genotype 2 and 3 than 
genotype 1, it is recommended that it is sufficient to implementation of a 48-week regime of treatment for 
genotype 1 and a 24 week therapy for genotypes 2 and 3 [122]. 
Two kinds of pegylated interferon-alfa (peg-IFN-α) are available, known as peg-IFN-α-2a and peg-IFN-α-2b 
being used as mono-therapy to treat HCV infections. In a review by Aman, 2012, it is shown that one week 
administration of peg-IFN-α-2a is more efficient than IFN-α-2a though peg-IFN-α treatment has some side 
effects including headache, weakness, haematological disorder, and injection site reaction [9]. Ribavirin is not 
recommended as mono-therapy for HCV treatment because it is more efficient in combined therapy. The 
highest sustained viral response (SVS) has been obtained by the combination therapy of peg-IFN-α-2a and 
ribavirin. This regimen is known as a current standard of care for chronic HCV patients who have not been 
treated previously [157]. Among 6 genotypes of HCV, 48 week combination therapy is recommended a 
standard treatment for genotype 1 and 4; 24 week combination regimen is proposed for genotypes 2 and 3 
[159]. 
The cost of antivirus therapy against HCV is expensive. The wholesale price of a 48-week therapy of peg-IFN 
plus ribavirin is about $30,000, while a comparable regime of non-pegylated IFN plus ribavirin costs between 
$15,000 and $20,000 [9]. The high cost of treatment of HCV patients makes it unaffordable for HVC patients in 
Asian countries located in the highest reported HCV prevalence rate [123]. Therefore, none-therapeutic 
treatment is another recommended approach to prevent HCV patients from developing liver diseases. After 
diagnosis of HCV infection, patients should change lifestyle to limit disease development and control further 
health consequences. These changes involve regular physical exercises; adopting healthy eating habits, and 
more importantly maintaining a healthy weight. It is believed that obesity in HCV patients plays a crucial role in 
fibrosis progression [160,161]. Patients should also avoid drinking alcohol and smoking as alcohol is reported as 
one of the major risk factor for liver diseases [162,163] and smoking may contribute to the development of 
diseases and increase the possibility of hepatocellular carcinoma progression [164]. 
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Approaches to control spread of HCV infection include primary and second prevention activities. Primary 
prevention activities are intended to reduce the risk of contracting HCV through main transmission routes. 
These involve virus inactivation in blood products; testing organs and blood donors; and providing counselling 
on risk reduction such as the use of contaminated drug needles, sexual intercourses with HCV infected partners 
and percutaneous exposure to infected blood in health care settings. Secondary prevention activities including 
counselling, identifying and testing people at risk; and treating HCV-infected patients, are aimed at reducing 
the risk for liver and other chronic diseases in HCV-infected patients [9]. 
COMPLICATIONS TO CHRONIC HBV AND HCV INFECTIONS 
The hepatitis B virus (HBV) still remains a major global public health problem. It is estimated that more than 
one million HBV-infected patients die annually of HBV-related liver disease or hepatocellular carcinoma. The 
prolonged immunologic response to HBV infection leads to the development of cirrhosis, liver failure, or 
hepatocellular carcinoma (HCC) in up to 40% of patients [165,166]. It is estimated that 15% - 40% of chronic 
HBV carriers develop severe liver disease complications during their lifetime and need treatment [167]. This is 
not only a problem in poor-resource countries, but also in developed countries such as France [168]. Long term 
risk of HCC and cirrhosis development is directly correlated with viral replication and serum HBV DNA level 
[169,170]. The role of viral genotype on the risk of HCC development is still identified [171]: in children, 80% of 
HCCs are present in cirrhosis genotype B patients, whereas young adults with HCC are mostly non-cirrhotic 
[36,172]. Furthermore, in adult, genotypes C and F increase the risk of HCC development [36,173,174]. Chronic  
HBV patients with persistent HBeAg seropositivity have a higher incidence (3.5% per year) of cirrhosis [175]. A 
long-term follow-up study in Korea involving 52 HBeAg negative and 136 HBeAg posivitive patients showed that 
age and persistent ALT elevation are independent factors for the development of cirrhosis decompensation, 
and HCC [176]. HCC develops at annual incidence of 3%-6% in individuals with cirrhosis and far less frequently 
in noncirhotic patients [177–179]. HBeAg seropositivity and HBV DNA level more than 2,000 IU/ml are 
significant factors for the development of cirrhosis and HCC, even in asymptomatic patients with chronic HBV 
infection [169,174,180,181].  
Nguyen et al. 2008 estimated the burden of HBV-related liver diseases in Vietnam and indicated that chronic 
HBV prevalence is likely reduce in Vietnam over the next two decades due to the implementation of universal 
infant HBV vaccination; however, the burden of HBV-related liver diseases will continue to increase. The 
estimated incidence of HBV-related liver cirrhosis increased 67% from 21 900 cases in 1990 to 36 500 cases in 
2005 and projected to be 58 600 cases by 2025. It is also predicted that HBV-related HCC incidence increased 
from 9 400 cases in 1 990 to 15 600 cases in 2005 and projected to be 25 000 cases in 2025. The projected 
annual HBV-related mortality increased from 12 700 cases in 1990 to 23 300 cases in 2005 and 40 000 cases in 
2025 [22]. 
Up to 170 million people worldwide are currently infected with HCV infection. Hepatitis C causes significant 
liver-related morbidity and mortality due to hepatic decompensation and development of hepatocellular 
carcinoma [182]. The most burden of HCV infection is recognised through the development of chronic liver 
disease and HCC, which is reported increasing incidence not only in developed countries, but also in developing 
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countries [123]. It is estimated that approximately 80% of HCV-infected individuals develop chronic infections 
and 20% - 30% of HCV-infected individuals are expected to clear the virus within six months of infection. 
Serious complications from HCV infection does not occur until 20 years after infection and 20% of chronic HCV 
carriers develop life-threatening cirrhosis and another 20% develop liver cancer [127,183]. The proportion of 
evolution to chronic HCV carriers after acute exposure to HCV was reported 92% in patients exposed to HCV 
genotype 1b infection compared with 35% to 50% in patients exposed to other HCV genotype [184]. Most HCV-
infected patients will die before onset of HCV-related complications, which are important public health 
problem, even though they occur in only a fraction of HCV-infected patients [123]. 
TEST ACCURACY: SENSITIVITY AN D SPECIFICITY 
Screening tests must qualify high sensitivity with a maximum specificity while exhibiting a low initial reactive 
rate , which may result in time saving and improve cost and effectiveness [13]. High test sensitivity plays a 
fundamental role in blood testing because it can minimise the false negative test results which may contribute 
to the risk of post transfusion infections. This section attempts to provide information on current test 
sensitivity for detection of HBsAg, anti-HBc and HBV DNA. 
Three are different units in literature regarding to express the test results. Positive test results are expressed in 
different ways either as international units (IU) or nanogram (ng) according to different standards. It is useful to 
know that one international unit (IU) is equivalent to 5.6 Abbott ng, 1.9 French ng according to WHO 
international standard [12]. One ng of HBV protein is equivalent to approximately 2 x 10
8
 22 nm sub viral 
particles and to approximately 5 x 10
7
 HBV particles with assuming that the virus particles have four times 
larger surface. Current assays for HBsAg vary in detection limits ranging from 0.04 to 0.62ng/mL. At a detection 
limit of 0.04ng/mL, there must be approximately 2 million particles in blood for a positive result test, and the 
excessive presence of sub viral particles can improve detection [40]. It is clear that screening blood donors for 
HBsAg even with highly sensitive assays does not eliminate the post transfusion of HBV transmission. There are 
some possible explanations for false negative results in current HBsAg assays. Firstly, blood donors with HBsAg 
mutant may escape detection by screening assays [185,186]. Secondly, virus diversity yields sequences that are 
not detected by antibodies employed in the assays [187]. Thirdly, the concomitant presence of anti-HBs 
resulting in the formation of circulating immune complexes not or poorly displaced by HBs Ag capture antibody 
[188]. 
A recent study on the efficacy of 70 HBsAg assays bought from open markets around the world were conducted 
by the International Consortium for Blood Safety (ICBS), on plasma units collected from blood banks around the 
world. The study showed the range of sensitivity between the most sensitive assays and the least sensitive 
HBsAg test kits was 0.021 IU/ml to more than 2.33 IU/ml in Paul-Ehrlich Institute (PEI) standard and 0.013 
IU/ml to more than 4 IU/ml in ICBS panel. This reflected a >300 fold difference between the most and the least 
sensitivity of the current assays for HBV detection. The study also documented that seventeen HBsAg EIA 
assays with high analytic sensitivity <0.13 IU/ml prove 100% diagnostic sensitivity and were even sensitive to 
the various HBV variants tested. Another six EIA assay demonstrated high sensitivity < 0.13 IU/ml, but missed 
HBsAg mutant and/or showed reduced sensitivity to some certain HBV genotypes. Twenty EIAs for HBsAg had 
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sensitivity of 0.13 – 1 IU/ml. Another eight EIA assays and 19 rapid tests had analytical sensitivity of 1 – > 4 
IU/ml. Those assays with sensitivity > 1 IU/ml significantly reduce the length of the HBsAg positive period 
resulting in less reliable HBsAg detection in asymptomatic HBV infection. These assays also showed lower 
analytical sensitivity to certain genotype. It should be noted that laboratories should take into account the 
analytical sensitivity for HBsAg test kits and check for the relevant HBV variants for a given population [189]. 
Many studies have been conducted to determine the efficacy of anti-HBc assays by testing anti-HBc positive 
blood samples for the presence of HBV DNA. As mentioned earlier, anti-HBc seems to have the potential of 
disqualifying majority of OBIs, leaving only the probably rare cases with HBV DNA alone undetected. However, 
anti-HBc tests demonstrate some limitations. For many years, the specificity of anti-HBc assays is far below the 
performance of anti-HIV and anti-HCV assays as well as the lack of confirmatory assays [88]. As required, assays 
for anti-HBc approved for blood screening must have a specificity of more than 99%, but the existence of 
confirmatory assays still remains a problem [190].  
The sensitivity of HBV DNA also has a crucial impact on results in a given population as the concentration of 
viral genome in anti-HBc samples was mostly less than 100 IU/mL The gold standard for OBI diagnosis is 
intended to explore the extracted DNA from liver or blood requiring a very specific and sensitive assay. Experts 
recommended assays with detection limit of 10 copies of HBV DNA per reaction [98]. Current assays for HBV 
DNA detection are nested PCR, real-time PCR, and transcription based mediated amplification. These assays 
can decline the lower detection limit of less than 5 copies/ml of HBV DNA. This is especially important in OBI 
due to the fact that HBV DNA varies from less than 10 to 425 copies/mL [40]. Detection of OBI requires the 
assays with the highest sensitivity and specificity with lower limit of detection less than 10 IU/mL for HBV DNA 
and <0.1 ng/mL for HBsAg [12]. 
KNOWLEDGE GAPS 
HBV and HCV infections are public health problem in developing countries and a leading cause of chronic liver 
diseases, cirrhosis, and hepatocellular carcinoma. Asian countries including Cambodia and Vietnam are 
classified as high prevalence areas of HBV and HCV infections. HBV and HCV share the common modes of 
transmission and can be transmitted horizontally and vertically. Blood transfusion is identified a frequent risk 
factor for both disease transmission. Screening test for HBsAg and anti-HCV in blood donors is in place in South 
East Asia including Cambodia and Vietnam whereas anti-HBc screening in blood donors is implemented in 
developed countries such as United States and Japan. It is documented that HBV transmission can be spread 
from HBsAg negative and anti-HBc positive blood donors to recipients when blood collected during the initial 
sero-negative window period of an acute HBV infection or during late stage where HBV DNA is present through 
HBsAg is negative, the so called ”OBI”. Anti-HBc screening helps to eliminate HBV transmission in window 
period, but is not practical in intermediate and endemic HBV prevalence where half of population carries anti-
HBc, resulting in the exclusion of vast number of blood donors. NAT tests are accurate, but not feasible due to 
high cost. In the current context of Vietnam and other countries in Southeast Asia, we have to find other mean 
of estimating the risk of transfusion-transmitted hepatitis B.  
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Rapid tests may be a feasible tool for detection of HBV infection in blood donors in poor communities. With the 
rapid test, one can run a single sample and the result can be available in a short time. However, it is reported 
that rapid tests may yield false negative results due to prozone effects when used in endemic HBV population. 
Enzyme Immunoassay (EIA) is considered as a standard test for HBV and HCV detection in South East Asia. 
However, the EIA test is expensive, not practical in rural remote district hospitals due to the fact that the EIA 
test is normally designed to run with a total of 96 blood samples including control samples in a single run. EIA 
tests for detection of HBV and HCV is regulated as a standard test in national guideline in Vietnam. However, 
the rapid tests for HBV and HCV detection were already in use in some parts in Cambodia. One may question 
how accurate the rapid test results are and what the potential risk of transmitted transfusion infection diseases 





















The overall objective of the thesis was to study the overall pattern of HBV and HBC infections in Southeast Asia 
in order to give advice to the public sector on how to avoid transfusion-transmitted HBV and HCV. This was 
done through the following specific aims:  
1. To examine the accuracy of rapid tests for detection of HBsAg, anti-HBc and anti-HCV in potential 
blood donor in rural Vietnam and Cambodia (paper 1) 
2. To estimate more accurate prevalence rates of HBV and HCV infections among potential blood donors 
in a rural area of Vietnam and to examine the accuracy of enzyme immunoassay (EIA) technique used 
for HBsAg, anti-HBc, anti-HCV testing of blood donors at a local laboratory in Vietnam (paper 2) 
3. To estimate the risk of transfusion-transmitted hepatitis B in Vietnam based on the available data on 
HBV prevalence and the estimated prevalence of OBI in blood donors established from current 

















MATERIALS AND METHODS 
STUDY POPULATION 
A cross-sectional epidemiological study on prevalence of hepatitis B and hepatitis C in potential blood donors in 
rural Cambodia and Vietnam was conducted in a multicentre design. The study was carried out in February-
June 2007 in Battambang and Pailin Provinces, Cambodia; and Quang Tri Province, Vietnam. In order to detect 
the prevalence differences between two populations in each country of at least 10% with a significance level of 
5% with two sided testing; and a test power of 90%, a total of 1,200 samples were required for the study in 
each country. Stratified sampling was applied to assess local prevalence variations in two equal subsamples, 
600 samples in each subsample in each country.  
The study population was the potential blood donors in the study area. Eligible participants were individuals 
aged 18 to 55, not vaccinated against HBV and living permanently in the study areas. Before collecting blood 
samples, villagers were informed by local health authorities that the study linked up to the introduction of safe 
blood transfusion service for the local population; that participation was voluntary and free of charge; that all 
participants would be informed of the test outcome and get medical advice and counselling accordingly. After 
the informed consent forms were signed with the witness of blood trained collectors, participants were asked 
to fill in and sign registration forms before inclusion.  
The study subjects for paper 1 include a total of 2,400 blood samples in both countries to examine the accuracy 
of one rapid test for detection of HBsAg, anti-HBc and anti-HCV; 1,200 blood samples collected from Vietnam 
were used for paper 2 to estimate the prevalence and identify the risk factors; and existing data from paper 2 
was used for the risk assessment model in paper 3. Sample collection procedures, screening tests used; and 
validation of the test accuracy is done according to the same study protocol in both countries. 
STUDY SAMPLES 
Paper 1: The study samples consisted of 2,400 female and male potential blood donors from rural Cambodia 
and Vietnam, 1,200 from each country. The mean age of the study population was 33.4 years (SD 9.5); 41 % 
were males. The ages did not differ significantly between the subjects from the two study countries, but the 
rate of female participants was slightly higher in Vietnam. The study participants in Cambodia included 677 
females and 523 males; the mean age was 32.8 years, with a range of 18 to 52 years. The voluntary participants 
in Vietnam were consisted of 730 females and 470 males with the mean age of 34.6 years (SD: 8.6) with a range 
of 18-55 years. 
Paper 2: In order to assess local prevalence variations the blood samples were collected with a stratified 
sampling procedure. Samples were collected with a stratified sampling procedure: 600 samples (mean age 35 
years, SD=8.4; female/male: 329/271) were collected from all villages in one remote rural area, Trieu Trach 
community (a total population of 6,801 persons, 3,510 female) with less developed health infrastructure, and 
600 samples (mean age 34.2, SD=8.8; female/male: 401/199) from all villages in an area with more developed 
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health infrastructure, Cam Thuy community (a total population of 4,994 persons, 2,557 female). Within each 
area, sampling sites at village level were established, and blood samples collected from the consenting 
individuals. With this sampling design, potential clustering of results at village level had to be considered and 
adjusted for in the prevalence estimates.  
Paper 3: A stochastic Monte Carlo models were used to estimate the probabilities of HBV transmission from 
OBI in different scenarios. Inputs to the model were based on data from the prevalence study in paper 2; 
literature review; and expert opinions. An existing database from a cross-sectional epidemiological study in a 
reference population of potential blood donors in rural areas of Vietnam was used as baseline data (Viet L et 
al., 2012). The study, hereafter named “the 2007 prevalence study”, was carried out in February-March 2007 in 
the Quang Tri province of Vietnam.  
EXPERT PANEL ESTIMATES OF OBI PREVALENCE  
As no certain estimates of OBI prevalence existed, this information for input into the simulation models was 
obtained by two independent international recognized experts in the field of our study, Dr. JP Allain (a) and Dr. 
R. Reddy (b). Both were asked to give their best qualified assumptions of OBI prevalence in a population with 
high, intermediate and low endemic HBsAg prevalence. This was used to produce an expert-based estimate on 
the OBI prevalence in Vietnam to be used in the simulation model. 
According to the expert panel, a wide range of OBI prevalence in blood donors has been reported; between 1:6 
and 1:50,000 globally, depending on the sensitivity of the NAT and HBsAg assays used, the prevalent genotype 
in a given population; and the efficacy of the host immune system (Allain JP, personal communication, 2011, 
[190]. In Vietnam, where HBV genotypes B and C are prevalent, the prevalence of OBI is likely around 1:1000 – 
similar to the situation in Taiwan and South China. The review by Allain and Candotti (2011) on OBI prevalence 
from blood donors in different studies in China, reported a range between 1:600 and 1: 21,000 blood units with 
a mean about 1: 1,000 blood donors [191]. OBI prevalence in blood donors in Taiwan was reported 
approximately 1: 1,000 blood units [110,111]. In South Africa where HBV prevalence in the population is 8-10%, 
the OBI NAT yield rate in first time donors is 1:3,545 (Ravi Reddy Expert panel, Personal communication, 2011). 
Because data on OBI prevalence in Vietnam is not available, we used the estimated prevalence of OBI of 
1:1,000 reported from China and Taiwan and also given by the expert panel as reference. The reasons for this 
decision are twofold: The genotypes B and C are prevalent in China, Taiwan and Vietnam [48,192–194] and 
both Taiwan and Vietnam are categorized as high-HBV prevalence countries according to the classification by 
WHO [5,22]. 
MONTE CARLO SIMULATION MODELLING 
Stochastic models are used to bring randomness and uncertainties into the final estimates and are often used 
when decisions under uncertainties are requested. To estimate the probabilities of HBV transmission in 
different scenarios, we established a stochastic Monte Carlo simulation model using the @Risk software (ver 
5.7, Palisade Corp. Ithaca, NY) add-in to Excel™. Inputs to the model were based on data related to HBsAg and 
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anti-HBc on actual analysis done by the authors and controlled in a Norwegian accredited microbiology 
laboratory from the 2007 prevalence study, literature review, and the expert panel estimates. The number of 
blood donors for the simulation was set at 1,000,000 corresponding to the expected number of donated blood 
units needed for health care system in Vietnam in 2012. The age structure of the population by gender was 
estimated based on data from the National Vietnam population and the housing census performed in Vietnam 
in 2009 using 18-29; 30-39; and equal and more than 40 as age groups. 
The crucial inputs of the model were the test sensitivities and specificities, first as specified by the producer, 
modelled using the beta function in @Risk, where e.g. a sensitivity with x/n positive is modelled as a Risk-Beta 
(x+1, n-x+1), and later modified with reducing the sensitivity by increasing the x by 2 and 5 respectively, to 
reflect a more realistic scenario when a test is used in many laboratories under various conditions where a 
reduced sensitivity must be expected. These estimates were used as inputs in various Risk-Binomial functions in 
the model. The true prevalence (TP) of the population was based upon results of apparent prevalence (AP) 
from the 2007 prevalence study calculated by the formula from Dohoo et al (2009), pooling gender/ age group 
estimates form this study and using as the starting point for further modelling:  
 
The Risk Triangular function was used for the population probability-distribution of OBI at three scenarios 
based upon the expert panel with a fixed lower value for OBI estimated prevalence of 0.0005, an expected 
(middle) value of 0.001, and upper values of 0.0015 (scenario I), 0.002 (scenario II) and 0.003 (scenario III) 
respectively. 
Thus, the model represents a combination of three OBI scenarios and three HBsAg EIA sensitivities, giving nine 
different scenarios for comparison. The simulation model first produced age/ gender groups from 1,000,000 
donors, and then calculated the true prevalence and the number in each of four groups based on of EIA test 
results. In the model, all HBsAg positive samples were removed and not used for transfusion. A main concern 
was to distinguish between HBsAg false-negative blood donors by EIA due to limited sensitivity and potential 
OBI defined as study persons with true negative HBsAg test and anti-HBc true positive and anti-HBc false 
negative. 
SAMPLE COLLECTION 
One blood sample of 5 ml was collected from each voluntary participant by trained laboratory technicians, set 
aside to be coagulated for 30 minutes, then centrifuged and cooled to 4 ºC in portable cooling boxes. The 
serum samples were then taken for analysis either at Battambang Blood Transfusion Centre in Cambodia or at 
Quang Tri Provincial Preventive Medicine Centre, Vietnam. Analysis was done within three days after sampling. 






The rapid tests in this study were already in use for blood donor screening in some parts of Cambodia. Three 
qualitative chromatographic immunoassays for HBsAg, anti-HBc, anti-HCV were used: ACON® HBsAg one step 
ultra, no. IHBsg-U302; ACON® anti-HBc one step, no. IHBcb-302; and ACON® anti- HCV one step, no. IHC-302 
(Acon Laboratories, San Diego, CA). The HBsAg test is made by a combination of monoclonal and polyclonal 
antibodies to selectively detect elevated levels of HBsAg in serum and plasma. The test can detect a limit of 0.5 
ng/ml for HBsAg for both ad and ay subtypes at concentrations from zero to 300 ng/ml. The anti-HBc test 
utilizes a combination of monoclonal antibodies and antigen to selectively detect elevated levels of anti-HBc in 
serum or plasma. The anti-HCV test utilizes a combination of protein A coated particles and recombinant HCV 
proteins to selectively detect antibody to HCV in plasma or serum. The recombinant antigen used in the test 
was encoded by genes for both structural and non-structural proteins. All three tests had an internal control 
(Acon laboratories, n.d.). The rapid tests were carried out according to the manufacturers’ instructions. The 
rapid test outcomes were compared to the test properties claimed by the manufacturer. Agreement analysis 
was undertaken to compare the overall rapid test outcomes with enzyme immunoassay (EIA) as a reference 
test.  
EIA TESTS 
The EIA reference test (Monolisa EIA Assay® BioRad; Monolisa® HBsAg ultra, no. 72348; Monolisa® anti-HBc 
plus, no. 72316; Monolisa® anti-HCV plus, no. 72318; BioRad Diagnostics, 92430 Marnes-la-Coquette, France) 
was carried out correspondingly either at Battambang Blood Transfusion Center in Cambodia or at the Quang 
Tri Provincial Preventive Medicine Center in Vietnam. The tests were carried out according to the 
manufacturers’ instructions. The actual EIA test has sensitivity and specificity for HBsAg of 100% and 99.94%; 
for anti-HBc of 99.53% and 99.5%; and for anti-HCV of 100% and 99.8%, respectively as claimed by producers. 
The EIA test measures a numerical ratio (S/CO) for classification of test-positives and test-negatives. Ratios 
lower than 1.0 were classified as negative results; ratios higher or equal to 1.0 were classified as positive 
results; units with a ratio in the range of 0.9-1.0 were classified as equivocal and reanalysed. 
Principle of the EIA assays 
Monolisa™ HBs Ag ULTRA assay is a one-step enzyme immunoassay based on the principle of the "sandwich" 
type using monoclonal antibodies and polyclonal antibodies selected for their ability to bind themselves to the 
various subtypes of HBs Ag now recognized by the WHO and the most part of variant HBV strains in human 
serum and plasma. The Monolisa™ HBs Ag ULTRA solid phase is coated with monoclonal antibodies and its 
conjugates are based upon the use of monoclonal antibodies from mouse and polyclonal antibody from goat 
against the HBs Ag. These antibodies are bound to the peroxidase. The sensitivity limit of the assay for HBsAg 
detection has been estimated < 0.060 ng/ml during the evaluation with the French SFTS 2001 panel of HBs 
antigen. The limit of detection has been estimated less than 0.130 IU/ml by testing the WHO 2nd International 
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standard NIBSC code 00/588 and found at 0.025 IU/mL CI95% [0.019 – 0.037 IU/mL]. The following sub-types 
from SFTS 2001 panel: adw2, adw4, adr, ayw1, ayw2, ayw3, ayw4, ayw5, and ayr, were all found positive with a 
ratio larger than 5 with Monolisa™ HBs Ag ULTRA. 
MONOLISA® anti-HBc PLUS is an enzyme immunoassay for the simultaneous detection of total antibodies to 
hepatitis B virus core in human serum or plasma. MONOLISA® anti-HBc PLUS is based upon the use of a solid 
phase prepared with recombinant HBc antigen. 
Steps of the MONOLISA® anti-HBc PLUS manipulation include as follow: 
Firstly, the sera to be tested and the control sera are added to the wells. The presence of antibodies to HBc in 
the sera will bind to the antigens fixed on the solid phase. Secondly, the peroxidase-labelled antibodies to 
human IgG and IgM are added after a washing step. Then they in turn bind to the specific antibodies captured 
on the solid phase. Thirdly, after removal of the unbound enzymatic conjugate, the antigen-antibody complex 
is revealed by addition of substrate. Finally, after the reaction has been stopped, the absorbance values are 
measured using a spectrophotometer at 450/620-700 nm. The absorbance measured for a sample allows the 
presence or absence of antibodies to HBc to be determined. The colour intensity is proportional to the quantity 
of anti-HBc antibodies bound on the solid phase. 
When performing the evaluations, the sensitivity of the MONOLISA® anti-HBc PLUS was evaluated using the 
Paul Ehrlich Institute IgG and IgM standards, and the limit of detection was estimated at 0.5 U PEI/ml and 8 U 
PEI/ml for the IgG and IgM respectively. 
MONOLISA® anti-HCV PLUS Version 2 is an indirect immuno-enzymatic technique for the detection of anti-HCV 
serum or plasma of HCV-infected patient. MONOLISA® anti-HCV PLUS Version 2 is based upon the use of a solid 
phase prepared with purified antigens: 3 recombinant proteins produced by E. coli from clones selected in the 
non-structural area (NS3 and NS4) and in the structural area of the hepatitis C virus genome. Detection is with 
goat anti-human IgG antibody purified by affinity chromatography and coupled to peroxidase. 
The performance of the MONOLISA® anti-HCV PLUS Version 2 includes the following reaction step: 
Firstly, the samples to be tested and the control sera are added to the wells. If antibodies to HCV are present, 
they will bind to the antigens fixed on the solid phase. Secondly, the peroxidase-labelled antibodies to human 
IgG are added after a washing step. They in turn bind to the specific antibodies captured on the solid phase. 
Thirdly, after removal of the unbound enzymatic conjugate, the antigen-antibody complex is revealed by 
addition of substrate. Eventually, after the reaction has been stopped, the absorbance values are read using a 
spectrophotometer at 450/620- 700 nm. The absorbance measured for a sample allows the presence or 
absence of antibody to HCV to be determined. The colour intensity is proportional to the quantity of antibody 




VALIDATION OF TEST ACCURACY 
The EIA test outcome was blindly validated with the Automated Chemiluminescent Microparticle Immunoassay 
Technique (CMIA; Architect® HBsAg, ref 6C36; Architect® anti-HBc, ref 7C17; Architect® anti-HCV, ref 6C37; 
Abbott GmbH & Co. KG, 65205 Wiesbaden-Delkenheim, Germany). A subset of 640 serum samples including 
321 samples from Vietnam and 319 samples from Cambodia (n =240 for each category, HBsAg, anti-HBc, and 
HCV) was randomly selected for validation at the Department of Microbiology, University Hospital of North 
Norway.  
The subset sample size (n = 240) was estimated in order to detect test indicator differences of more than 5% 
with 95% confidence, the subset being selected to get at a balance of 2/3 assumed test-positive units versus 
1/3 assumed test-negative units. With the CMIA testing of HBsAg in Norway, samples with values less than 0.05 
IU/ml were classified negative and those with values greater than or equal to 0.05 IU/ml were classified 
positive. CMIA analysis of anti-HBc and anti-HCV was based on the ratio of the signal to the cut-off value 
(S/CO). A ratio less than 1.00 was defined as negative, and a ratio greater than 1.00 was defined as positive. 
Ratios in the range of 0.90-1.00 were considered as equivocal and re-analysed.  
In paper 1, a high agreement between the EIA and CMIA test outcomes were reported with kappa values 
higher than 0.8 for HBsAg, anti-HBc, and anti-HCV detection. Based on these results, the EIA test outcomes for 
HBsAg, anti-HBc, and anti-HCV in the total study population (n = 2,400) were used as a reference for evaluation 
of rapid test accuracy in the actual study. 
Principles of the assays:  
The ARCHITECT HBsAg assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative 
determination of HBsAg in human serum and plasma. In the first step assay performance, sample and anti-HBs 
coated paramagnetic micro particles are combined. HBsAg present in the sample binds to the anti-HBs coated 
micro particles. After washing, acridinium-labeled anti-HBs conjugate is added in the second step. Following 
another wash cycle, Pre-Trigger and Trigger Solutions are added to the reaction mixture. The resulting 
chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the 
amount of HBsAg in the sample and the RLUs detected by the ARCHITECT i*optical system. The concentration 
of HBsAg in the specimen is determined using a previously generated ARCHITECT HBsAg calibration curve. If the 
concentration of the specimen is greater than or equal to 0.05 IU/mL, the specimen is considered reactive for 
HBsAg. 
The ARCHITECT anti-HBc assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the qualitative 
detection of antibody to anti-HBc in human serum and plasma. In the first step, sample, assay diluent, and HBc 
antigen coated paramagnetic micro particles are combined. Anti-HBc present in the sample binds to the HBc 
antigen coated micro particles. After washing, anti-human acridinium-labeled conjugate is added in the second 
step. Following another wash cycle, Pre-Trigger and Trigger Solutions are added to the reaction vessel. The 
resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists 
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between the amount of anti-HBc in the sample and the RLUs detected by the ARCHITECT i* optical system. The 
presence or absence of anti-HBc in the specimen is determined by comparing the chemiluminescent signal in 
the reaction to the cut-off signal determined from a previous calibration. If the chemiluminescent signal in the 
specimen is greater than or equal to the cut-off signal, the specimen is considered reactive for anti-HBc. 
The ARCHITECT Anti-HCV assay is a chemiluminescent micro particle immunoassay (CMIA) for the qualitative 
detection of antibody to hepatitis C virus (anti-HCV) in human serum and plasma. In the first step, sample, 
recombinant HCV antigen coated paramagnetic micro particles and Assay diluent are combined. Anti-HCV 
present in the sample binds to the HCV coated micro particles. After washing, anti-human acridinium-labeled 
conjugate is added in the second step. Following another wash cycle, Pre-Trigger and Trigger Solutions are 
added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units 
(RLUs). A direct relationship exists between the amount of anti-HCV in the sample and the RLUs detected by 
the ARCHITECT i* System optics. The presence or absence of anti-HCV in the specimen is determined by 
comparing the chemiluminescent signal in the reaction to the cut-off signal determined from a previous 
ARCHITECT Anti-HCV calibration. If the chemiluminescent signal in the specimen is greater than or equal to the 
cut-off signal, the specimen is considered reactive for anti-HCV. 
STATISTICAL PLATFORM 
Continuous variables were expressed as mean value with 95% confidence intervals constructed by the Student 
procedure. Categorical variables are presented in contingency tables with 95% confidence intervals, and the chi 
Square was used to test the difference between two groups. The Kappa (κ) analysis was used to express 
agreement between test methods; κ-values of 0.4-0.6 were classified as having acceptable agreement, values 
of 0.6-0.8 as having high agreement, and values of 0.8-1 as having very high agreement. In paper 2, a 
multivariable logistic regression model was established to test if observed differences between areas were due 
to sampling biases. Model fit was assessed using the Hosmer-Lemeshow test and Receiver Operating Statistics 
Curves (ROC). Different statistical techniques were employed using the software JMP® for Windows (ver 8.0, 
SAS Institute Inc.) or Stata (SE/11 for Windows, StataCorp. College Station, TX). 
ETHICAL CONSIDERATIONS 
Informed consents were obtained after orally and written information was given by local health authorities. 
Medical counselling according to the test outcomes was granted to all voluntary participants. The consent form 
was signed on-site in fields before the blood samples were collected. Written files of demographical and 
laboratory data were stored in locked steel shelves at the Quang Tri Preventive Medicine Centre, Vietnam; and 
at the Trauma Care Foundation head office in Battambang, Cambodia. Access to non-anonymous data was 
restricted to members of the research team. The study protocol was ethically approved by the Quang Tri 
Health Service, and by Quang Tri Provincial People’s Committee, Vietnam (Decision No. 2472/QD-UBND, 
20/12/2006); and by the Cambodian Committee for Research Ethics (ref 023 NECHR, 2/4/2007). All data were 






The actual rapid tests were observed with high specificity for all three HBsAg, anti-HBc and anti-HCV tests as 
claimed by the manufacturer. The test sensitivity was found significantly lower than that claimed by the 
producers: 86.5% for HBsAg; 86.6% for anti-HBc; and 76.4% for anti-HCV compared to >99%; 96.3%; and 96.8% 
respectively as claimed by the producers. There were large and significant variations in test performance 
between Vietnam and Cambodia, particularly for HBsAg detection. The sensitivity was significantly lower and 
the rate of false-negatives significantly higher for HBsAg and anti-HBc in the Vietnamese subsample compared 
to the Cambodian subsample. For the anti-HCV test, the sensitivity was observed low in Cambodia; inter-
country comparison could not be done because few HCV serum samples were positive for anti-HCV in Vietnam. 
The low sensitivity of the actual rapid tests for HBsAg, anti-HBc and anti-HCV make them useless for blood 
donor screening in rural Southeast Asia. 
PAPER 2 
In the study population, the prevalence of HBsAg was 11.4% (95% CI 9.6 – 13.2) and the prevalence of anti-HBc 
was 51.7% (95% CI 48.8 – 54.5). The prevalence was found higher in males than females. The prevalence of 
anti-HCV was observed at 0.17%. The test agreement between the EIA and CMIA techniques was found to be 
high both for HBsAg detection (κ = 0.91; 95% CI 0.83 – 0.99) and for anti-HBc detection (κ = 0.89; 95% CI 0.81 -
0.97). The positive and negative predictive values of the EIA tests compared to CMIA tests were observed to be 
94.9% (95% CI 87.5 – 98.6) and 97.5% (95% CI 86.8 – 99.9) for HBsAg respectively; and 92.4% (95% CI 84.2 – 
97.2) and 100% (95% CI 91.2 – 100) for anti-HBc.  
PAPER 3 
With 1,000,000 blood donors running in the model, the potential OBI ranged from 658 to 747 blood units at 5 
percentile and from 1,342 to 2,507 blood units per million at 95 percentile resulting in the risk for post-
transfusion hepatitis ranging from 66 to 250 blood units per million assuming that risk of post-transfusion from 
potential OBI is 10%. Using the manufacturer’s HBsAg sensitivity, the mean rate of blood units per million 
donations having false-negative HBsAg results was 298 (5-95 percentile: 14-893). When the test sensitivity was 
set lower and more in accordance with the local testing results, false-negative tests was observed at a mean of 
1,087 per million (5-95 percentile: 762-3220). The fraction of potential OBI was found to increase with 
increasing age groups in both male and female. In the male group, this fraction was found to be 0.33; 0.44; 0.70 







In a cross-sectional study some errors related to the sampling of study participants may exist. Though the study 
was aimed at potential blood donors we cannot exclude the possibility of having included some individuals with 
risk behaviour such as drug users. In order to control this, local health workers as well as local authorities were 
mobilised to recruit voluntary participants according to the inclusive criteria for the establishment of local 
blood transfusion services. Therefore, we believe that such bias if any should be moderate and without 
systematic or significant effect on the main outcome variables.  
Another concern is that selection bias due to spontaneous recruitment may have occurred in the study groups. 
Thus, we observed an imbalance of gender participants in Vietnam. As we can see that rate of female/male in 
Trieu Trach (3510/3291=1.07) is similar to rate of female/male in Cam Thuy (2557/2437=1.05); however, the 
sex ratio in the actual study population is 740/470= 1.57. We could not control the sex ratio of the study 
samples as participation was voluntary. We used only one community health centre in each area in Vietnam to 
collect blood samples, hence any person turning up and meeting the selection criteria was included, 
irrespective of gender. We could have met a sex distribution of 1:1 by refusing women to entry the study when 
300 women had been included at each site. However, this would also have meant a biased selection. We tried 
to adjust for this in the statistical analyses by detection of potential clustering phenomena. Our prevalence 
estimates were adjusted according to the geographical design. The multivariable model allowed us to adjust for 
the potential bias linked to age and gender, showing that there was no statistically valid difference between 
areas, and that estimates were influenced by the age/ gender in the sampled population. In conclusion, we 
maintain, that we do not expect our conclusions to be much influenced by potential bias linked to the study 
design. 
Next, failures regarding the technical sampling and processing in field may have happened. To control for this, 
all laboratory technicians collecting the blood sample in field were trained and all procedures were performed 
strictly according to the protocol under close supervision of the research team. No accidental events were 
reported and we feel confident that there have not been technical errors of significant impact.  
Also, one should scrutinize the accuracy of laboratory analysis. Only one experienced microbiological technician 
was assigned to process blood samples in field and analyse the serum samples in the laboratory. During the EIA 
analysis, all samples with test outcome close to the EIA cut-off level were re-analysed before test results were 
registered in the database. Also the EIA technique used for analysis was validated blindly by CMIA analysis at a 
high-tech Norwegian medical laboratory. A very high agreement between the two test outcomes (EIA and 
CMIA) was observed; therefore we hold that the actual prevalence estimates are reliable. 
In the Monte Carlo model, the inputs in the model were based on rather limited data related to HBsAg and 
anti-HBc prevalence conducted in Quang Tri Vietnam; literature review; and the expert panel estimates. The 
inputs are not evidence-based and one may question that the estimated risk of transfusion-transmitted HBV in 
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Vietnam may be imprecise. It is clear that the estimate relies on the input parameters. Although our estimates 
are consistent with the residual risk of HBV post-transmission reported recently [119,195] in other high 
endemic HBV prevalence, we still need further studies of OBI in blood transfusion in order to more precise 
estimate the risk for future strategy of transfusion settings.  
DISCUSSIONS OF MAIN RESULTS 
THE ACCURACY OF RAPID TESTS 
Paper 1 reveals three main findings. First, the accuracy of the rapid test for qualitative detection of HBsAg, anti-
HBc and anti-HCV in potential blood donors in rural Southeast Asia, is low. For detection of HCV the false -
negative rate was about 20%. Second, there was a significant difference between the observed and producer -
claimed test sensitivities for all three test assays. Third, significant differences in test sensitivity between two 
sub-populations in Cambodia and Vietnam were observed. 
One may question the reliability of the local reference test used for assessment of rapid test performance. As 
stated in the first part of the discussion, during EIA analysis in Cambodia and Vietnam, all study blood samples 
with a test outcome close to the EIA cut-off levels were re-analysed before test results were registered in the 
database. EIA analysis was also validated blindly by CMIA technique in a representative subset of the study at a 
Norwegian medical laboratory of high standard demonstrating high agreement (κ >0.8) between the reference 
test (EIA) and the CMIA test outcomes for HBsAg, anti-HBc, and anti-HCV. Therefore, there should be no reason 
to doubt the accuracy of the reference test used in the study.  
The study was conducted among potential blood donors in rural populations in Vietnam and Cambodia where 
hepatitis is endemic and both antigen and antibody levels may be high. Therefore a prozone effect may be one 
reason why some true positive results turned out to be negative with the rapid tests. Cross reacting antibodies 
may also influence the test results. There may also be test flaws due to genotype variations that may affect test 
sensitivity. For both HBV and HCV there are genotype differences between Western countries and Southeast 
Asia. HCV is an extremely variable virus with six different genotypes and more than 70 subtypes; HCV genotype 
6 is found to be dominant in Southeast Asia, with large subgenotypes differences between countries, e.g. 
Vietnam: 6a and 6d/e, Cambodia: 6q, Thailand: 6f, 6i/j, 6m and 6n [196–198]. For HBV, the genotypes B and C 
are the most common in Southeast Asia, while genotypes A and D are dominant in Europe [31,32].The low 
sensitivity and the large difference in sensitivity between countries, especially for HCV, can be related to 
deficient detection of genotypes and/or subtypes with the tests. Therefore, test accuracy in one study 
population or in one study country does not mean good performance in another population. 
The relatively good rapid test specificity, but the low sensitivity with many false negative rapid tests having 
reference test results far above the cut-off level by itself, indicates the poor rapid test performance in the study 
population is real. Previous study to evaluate the accuracy of HBsAg and anti-HCV assays in blood donors in 
Equador documented there was significantly higher false-negative rate for rapid test in comparison with EIA 
test outcomes [199]. A study conducted by Lien et al. 2000 to evaluate the three different rapid tests for 
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detection of HBsAg in 117 Vietnamese participants (not including ACON test) showed the tests performed well, 
but one test had a false-negative rate of 3-4% [200]. In our study with larger sample size we found significant 
difference in test performance; there may be some uncontrolled variables that may influence the test 
outcomes such as prozone effects and genotype difference. This means that the use of rapid tests must be 
questioned. One can predict that the use of rapid test have resulted in transfusion of infectious blood to 
patients. 
THE PREVALENCE ESTIMATES 
The actual study documents high prevalence of HBV infection in the rural study area in Vietnam and thus 
confirms the findings in previous smaller epidemiological studies conducted in rural as well as urban 
Vietnamese populations from which prevalence rates of HBV infection were reported in the range of 8% to 25% 
[21,22]. Due to the size of our present study samples, we believe that the prevalence estimates are solid with 
narrow confidence limits for the studied population of potential blood donors. Although there was a gender 
bias in the main sample, the actual study indicates that gender is a risk variable, men having a higher risk of 
HBV infection among studied population than women.  
The study also reports a high prevalence of anti-HBc (51.7%) in the study area consistently with previous survey 
estimates from Thanh Hoa province in Vietnam (49.7%) [21]. Blood samples being HBsAg negative and anti-HBc 
positive (42.2%) indicate that HBV infections have been endemic in the study area for some time. We also 
found higher prevalence of anti-HBc in the less developed community. However, the difference was moderate 
(10%) and hardly of medical significance. One may question the risk of HBV transmission from HBsAg negative 
and anti-HBc positive blood donors in the study population. The accurate estimates cannot be given because 
the present study participants could not be tested for HBV DNA due to limited resources. The rate of HBV DNA 
detected in HBsAg negative samples is reported to vary with the prevalence of HBV infection: less than 5 per 
cent in low HBV infection such as European countries and as high as 24 per cent in high HBV prevalence areas 
[4,17,201].  
Out of 1,200 studied samples, only two were anti-HCV positive with EIA technique. Of the two, one was also 
positive for both HBsAg and anti-HBc; the other was HBsAg negative and anti-HBc positive. Two more anti-HCV 
positive samples were found with CMIA technique in Norway. The finding of HCV infection in our study area 
corresponds well with prevalence estimates at 0.4% HCV infection reported in two different districts of Thanh 
Hoa province, Vietnam [149]. The two clearly missed anti-HCV positive blood samples by EIA picked up by CMIA 
analysis may be due to test properties. There are HCV genotype differences between Western countries as East 
Asia. Genotype C6 of HCV is found to be dominant in South East Asia, China and South Africa whereas it is less 
common in other part of the world [67]. The test in use was developed by a Western company, and it may be 





ESTIMATING THE RISK OF TRANSFUSION TRANSMITTED HEPATITIS B IN VIETNAM 
An important problem is the risk of virus transmission from OBI donors and/or blood donors collected during 
window period where HBsAg is undetectable and cases where there is a false negative test result. In the actual 
study population the rate of HBsAg negative, anti-HBc positive participants was high (42.2%) which raises the 
question of how many of these are also OBI cases and potential transmitters of HBV infection? Accurate 
estimates cannot be given because the actual study participants due to resource restrictions could not be 
tested for HBV-DNA. The rate of HBV DNA detected in HBsAg-negative samples is reported to vary with the 
prevalence of HBV infection. Less than 5% of HBsAg negative, anti-HBc positive blood donor samples are 
reported to have detectable HBV DNA in European countries with low HBV prevalence, whereas the 
corresponding rate is as high as 24% in areas with high HBV prevalence [4,17,201].  
 We report a method to estimate the OBI in Vietnam by a stochastic Monte Carlo model approach to perform 
risk assessment for transfusion-transmitted hepatitis B. The model estimates OBI from HBsAg negative and 
anti-HBc positive blood donors in Vietnam at the range from approximately 660 to 2500 per million blood units 
using the producer-specific test information. In Vietnam around 50% of the population is anti-HBc positive. If 
we assume that individuals in this subpopulation of blood recipients are immune-competent, the risk of HBV 
transmission is probably not higher than 10% (Allain JP, 2011, personal communication). Assuming that the risk 
of post transfusion HBV from OBI donors is 10% as maximum, we then estimate the risk of post transfusion 
HBV to be 66 to 250 per million, which is consistent with the residual risk in transfusion-transmitted HBV 
transmission reported in other high endemic HBV prevalence areas [119]. The prevalence of HBsAg in first time 
blood donors in Hong Kong (approximately 8%) was similar to that found in our potential first time donors in 
the actual study in Vietnam; however, over the last decades the prevalence of HBsAg in Hong Kong has been 
reduced to 1.83% (Ultrio screening period 2007-2009) and 1.13% (Ultrio Plus screening period 2009-2011). In 
these periods the Ultrio and the more sensitive Ultrio Plus assay detected OBI yield rates of 130 and 335 per 
million first time donations, respectively [195]. When adjusted for the HBsAg carrier rate (114 /1200=9.5%) in 
our present study one would expect a (8: 1.83) x (9.5:8) = 5.2 (Ultrio screening period) and (8: 1.13) x (9.5:8) = 
8.4 (Ultrio Plus screening period) higher OBI yield rate in Vietnamese first time donors compared with Hong 
Kong first time donors. When the HBsAg carrier rate indeed corresponds linearly to the OBI rate in South East 
Asia one would predict an OBI yield rate of 130 x 5.2= 676 per million for the Ultrio assay and equivalent to 335 
x 8.4= 2814 for the more sensitive Ultrio Plus assay. These data is corresponding to the estimates of the Monte 
Carlo model based on an estimated OBI rate of 1:1000. 
A recent multicentre look back study estimated 24% probability of OBI transmission by red blood cells (RBC), 
85%-100% by fresh frozen plasma (FFP), 51% by platelet concentrates (PCs), and 48% for all blood products 
from OBI donors that are anti-HBs positive ( 50% OBI carriers are anti-HBs positive with concentration more 
than 10 mIU/mL) [202]. If half of the estimated 676 per million OBI donors (based on extrapolations from Ultrio 
Hong Kong data) were potentially infectious (anti-HBs negative) and 50% of recipients in Vietnam would be 
susceptible (anti-HBc positive/anti-HBs prevalence unknown) one would predict that 0.50 x 0.5 x 0.24 x 676 = 
41 OBI transmissions per million RBC recipients would occur in Vietnam. If the Ultrio Plus instead of the Ultrio 
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OBI yield rate in Hong Kong first time donors is used for the projections, the transmission rate would be 0.5 x 
0.5 x 0.24 x 2814 = 169 OBI transmissions per million RBC recipients. These estimates are somewhat lower than 
the 60-250 cases estimated by the Monte Carlo modelling. However, taking the OBI transmission from all blood 
product (48% vs. 24%), OBI yield rate would be double (82 and 338 transmission per million respectively for 
Ultrio and Ultrio Plus assays). These estimates would be higher for PCs and FFP recipients in Vietnam. It is clear 
that the estimate depends on the input parameters and further study on OBI transmission in Vietnam is 
recommended. 
More importantly, false negative HBsAg blood samples are observed at a mean of 298 (5-95 percentile: 14-893) 
blood units per million in the model at producer-claimed sensitivity If more realistic test properties are taken 
into consideration, the mean rate of false negative HBsAg is found to be 1,087 per million blood units (5-95 
percentile: 762-3220) as lower test sensitivity at local laboratories was reported in Cambodia and Vietnam 
[203,204]. This shows the importance of test sensitivity and demonstrates that low HBsAg test sensitivity is the 
main cause of transfusion-transmitted HBV infections in Vietnam. 
It is documented that HBV transmission can spread through HBsAg negative and anti-HBc positive blood donors 
to recipients. Under the current context of Vietnam, HBsAg screening is a routine practice in blood banks, anti-
HBc screening and/or NAT can be performed, but in a limited scale in capable laboratories under the approval 
of health authorities. Data on OBI prevalence in Vietnam is limited. It is essential to perform some pilot studies 
on the prevalence of anti-HBc in HBsAg negative blood donors and testing for HBV DNA on those potential OBI 
blood donors to get precise estimate of OBI in blood setting for future blood safety.  
CONCLUSIONS  AND RECOMMENDATIONS  
Our study demonstrates that low sensitivity of the actual rapid tests for HBsAg, anti-HBc and anti-HCV make 
them useless for blood donor screening in rural Southeast Asia. Rapid tests may be useful screening tools in 
blood transfusion services in low-resource settings, but tests should be carefully validated locally before being 
used for screening purposes since test performance varies by location. 
The prevalence study shows that hepatitis B virus infection is endemic in rural areas of Vietnam and that 
almost half the population is or has been infected with HBV. Hepatitis C infection is rare, but false negative test 
results cannot be ruled out. The results also indicate that the EIA performance in blood donor screening in 
Vietnam may be sub-optimal, missing 2.5% of hepatitis B virus carriers and falsely excluding more than 7% of 
blood donors. As the prevalence of hepatitis B infection is high, occult hepatitis B infection may represent a 
threat to safe blood transfusion. We previously reported that Nucleic Acid Amplification Testing for HBV should 
be considered for blood donor screening in Vietnam in the future. However, using Monte Carlo modelling to 
develop a solid risk estimate of transfusion transmitted HBV from OBI we found that the dominant risk of post 
transfusion comes from HBsAg false negative blood donors and blood donors with OBI. In order to reduce the 
risk of HBV infection after transfusion, the focus should be to implement the best possible locally validated 
HBsAg test rather than spending resources on expensive NAT testing. Implementation of anti-HBc screening is 
not feasible at present since 50% of the donors would be deferred.  
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RECOMMENDATIONS FOR FUTURE STUDIES 
In Vietnam and some other countries in Southeast Asia, EIA test for HBsAg is compulsory to perform for blood 
donors in addition to anti-HCV, HIV, malaria, syphilis; however, current EIA test for HBsAg detection of blood 
donors in Southeast Asia documents that false-negative test for HBsAg due to low sensitivities imposes a 
dominant risk of post HBV transmitted transmission. In the meantime, best possible locally validated HBsAg EIA 
assays are optimal for HBsAg detection than anti-HBc tests as well as costly NAT in Southeast Asia in general 
and in Vietnam in particular. It is recommended that key laboratories at national level and at regional level 
should continuously monitor the test quality and take into account the analytical sensitivity for HBsAg assays 
including EIA and rapid tests; check the relevant HBV variants circulating for a given population. It is preferable 
to select more sensitive EIA test for HBsAg detection as low sensitive HBsAg assays are the predominant cause 
of transmitted-transfusion HBV in the region. 
Rapid tests can be used for first-line screening for blood donors to exclude all positive test results in remote 
areas. Then the accumulated negative blood donors in some remote areas should be gathered and confirmed 
by EIA tests in high laboratories to identify the false negative test results. Not all blood donors in Southeast Asia 
are first time donors, and repeat testing in duplicate in first time and/or regular donors not only declines the 
potential infectivity among blood donors, but is also likely to increase the amount of eligible blood products. 
This may even be more cost-effective because the cost of discarding positive blood bags is likely to be higher 
than the reagent cost of extra testing. 
The present study attempts to extrapolate information from rather limited studies in Quang Tri province and 
relevant OBI prevalence to form a national pattern for estimating risk for transfusion-transmitted hepatitis B in 
Vietnam as currently we have limited data elsewhere from Vietnam. Further studies of OBI in Vietnam are 
recommended in blood transfusion settings in order to more precisely estimate the OBI prevalence for future 
strategy of transfusion safety. Our simulation model can be used and developed for this purpose, as more data 
will be made available. 
It is documented that transfusion-transmitted infectious diseases are severe side effects of blood transfusions. 
There are several solutions to make blood transfusion safer. First of all, transfusions must be given to patients 
on strict indications and there is a room for improvement on evidence-based use of blood and blood 
components. Secondly, blood products from non-remunerated voluntary repeat donors (NRVRD) are safer than 
from family and replacement donors. Vietnam government has made efforts to build up Regional and Sub-
regional Blood Transfusion Centres across the country to increase number of NRVRD and should work toward 
100% NRVRD which always must be kept in mind for politicians and health care workers. Also, donor selection 
may be a challenge in areas endemic for hepatitis, malaria and dengue fever. What is considered proper donor 
selection in Vietnam may result in the exclusion of too many donors and the lack of sufficient blood supply in 
the country. Lastly, pathogen reduction of all donated blood units should also be considered. This method is 
not available for whole blood yet and is in general too expensive for low-resource countries. However, in the 
future, pathogen reduction may be a measure that will further increase the safety of blood transfusion. 
53 
 
HBV vaccines have been integrated in National Universal Immunization Program of infants in Vietnam since 
2003. Vietnamese blood donors can be currently divided into two groups: a) non-vaccinated and non-infected, 
and b) non-vaccinated but being infected or potential OBI cases. Recipients can be grouped as a) non-
vaccinated and non-infected; b) non-vaccinated but infected or being potential OBI cases; and c) vaccinated 
children less than 10 years old. Blood from non-vaccinated and non-infected donors is safe for all three groups 
of recipients. Blood transfusion from non-vaccinated but sero-positive donors may include OBI blood. If donors 
have a level of anti-HBs≥ 100 IU/ml, the transfusion is considered safe for all three groups of recipients. Quality 
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